0001437749-26-005891 | 10-K | XBRL Viewer

Significant Accounting Policies [Text Block]

Note 2—Significant Accounting Policies

The significant accounting policies followed in the preparation of these consolidated financial statements are as follows:

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

Segment Reporting

Management has determined that the Company operates in one reporting segment, which is the development and commercialization of innovative products to enhance cancer care. The Company derives its global product, license and royalty revenue through the sales of NERLYNX®. The majority of our royalty revenue is derived from our sub-licensee sales into China. The accounting policies of this operating segment are the same as those described below in Note 2–Significant Accounting Policies.

The Company's Chief Operating Decision Maker (“CODM”) is its President, Chief Executive Officer and Chairman of the Board, Alan H. Auerbach. The CODM primarily uses our Consolidated Statement of Operations and related revenues, expenses and net income in evaluating the performance of the single operating segment and determining how to allocate resources of the Company as a whole, including its sales force and related marketing, research and development programs, including alisertib, and licensing strategy. Consolidated revenue, expenses and net income are also used to monitor budget versus actual results.

In addition to the significant expense categories included within consolidated net income presented on the Company's Consolidated Statements of Operations, see below for disaggregated amounts that comprise operating expenses:

	For the Year Ended December 31,
	2025		2024		2023
Cost of sales	$	58,157	$	64,404	$	62,682
General and administrative		25,553		36,749		37,892
Commercialization		41,010		37,849		45,132
Research and development:
Clinical research and development		31,754		24,715		17,784
Medical affairs		5,494		4,605		6,751
Other research and development (1)		22,160		22,935		22,508
Operating costs and expenses		184,128		191,257		192,750
Stock based compensation		6,944		8,245		10,247
Total operating costs and expenses	$	191,072	$	199,502	$	202,997

(1) Other research and development expense includes regulatory affairs, pharmacovigilance, quality assurance, chemical manufacturing and other costs.

Use of Estimates

The preparation of consolidated financial statements in conformity with Generally Accepted Accounting Principles ("GAAP") in the United States requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the balance sheet, and reported amounts of revenues and expenses for the period presented. Accordingly, actual results could differ from those estimates.

Significant estimates include estimates for variable consideration for which reserves were established. These estimates are included in the calculation of net revenues and include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products. Other significant estimates include those related to the valuation of deferred income taxes, legal and other expense accruals.

Reclassifications

Certain prior year amounts in the Consolidated Statements of Cash Flows have been reclassified to correct an error in the prior year's presentation. Specifically, for the year ended December 31, 2024, a change in deferred tax assets of $7.1 million was previously classified within "Changes in operating assets and liabilities." This amount has been reclassified to non-cash items within the operating activities section of the Consolidated Statements of Cash Flows. This reclassification had no impact on the total net cash provided by (used in) operating activities, net income, or the Consolidated Balance Sheets for any period presented.

Net Income per Share of Common Stock

Basic net income per share of common stock is computed by dividing net income available to common stockholders by the weighted average number of shares of common stock outstanding during the periods presented, as required by Accounting Standard Codification ("ASC 260"), Earnings per Share. For purposes of calculating diluted net income per share of common stock, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents, such as stock options, restricted stock units (“RSUs”) and warrants. A common stock equivalent is not included in the denominator when calculating diluted earnings per common share if the effect of such common stock equivalent would be anti-dilutive.

Our potentially dilutive securities include potential common shares related to our stock options and RSUs granted in connection with the Puma Biotechnology, Inc. 2011 Incentive Award Plan and the Puma Biotechnology, Inc. 2017 Employment Inducement Incentive Award Plan. Diluted earnings per share (“Diluted EPS”) considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect. Diluted EPS excludes the impact of potential common shares related to our stock options in periods in which the option exercise price is greater than the average market price of our common stock for the period. The following potentially dilutive outstanding common stock equivalents for the respective periods were excluded from diluted net income per share because of their anti-dilutive effect:

	For the Year Ended
	December 31,
	2025		2024
Options outstanding		3,504,811		3,533,693
Warrant outstanding		2,116,250		2,116,250
Unvested restricted stock units		110,902		734,236
Totals		5,731,963		6,384,179

Revenue Recognition

Under ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”) the Company recognizes revenue when its customer obtains control of the promised goods or services in an amount that reflects the consideration that the entity expects to be entitled in exchange for those goods or services. The Company had no contracts with customers until the FDA approved NERLYNX on July 17, 2017. Subsequent to receiving FDA approval, the Company entered into a limited number of arrangements with specialty pharmacies and specialty distributors in the United States to distribute NERLYNX. These arrangements are the Company’s initial contracts with customers. The Company has determined that these sales channels with customers are similar.

Product Revenue, Net

The Company sells NERLYNX to a limited number of specialty pharmacies and specialty distributors in the United States. These customers subsequently resell the Company’s products to patients and certain medical centers or hospitals. In addition to distribution agreements with these customers, the Company enters into arrangements with healthcare providers and payors that provide for government mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products.

The Company recognizes revenue on product sales when the specialty pharmacy or specialty distributor, as applicable, obtains control of the Company's product, which occurs at a point in time (upon delivery). Product revenue is recorded net of applicable reserves for variable consideration, including discounts and allowances. The Company’s payment terms range between 10 and 68 days.

Product revenue also consists of product sales under sub-license agreements to our sub-licensees, who then sell into their respective international territories.

Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales.

If taxes relating to product sales should be collected from customers and remitted to governmental authorities, they will be excluded from revenue. The Company expenses incremental costs of obtaining a contract when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. However, no such costs were incurred during the year ended December 31, 2025.

For the year ended December 31, 2025, five customers individually comprised approximately 27.3%, 17.0%, 16.4%, 13.1% and 10.6%, respectively, of the Company’s total product revenue. For the year ended December 31, 2024, four customers individually comprised approximately 28.4%, 18.8%, 14.1% and 12.3%, respectively, of the Company’s total product revenue. For the year ended December 31, 2023, four customers individually comprised approximately 31.4%, 17.2%, 15.2% and 11.9%, respectively, of the Company’s total product revenue.

Reserves for Variable Consideration

Revenue from product sales is recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. Components of variable consideration include trade discounts and allowances, product returns, provider chargebacks and discounts, government rebates, payor rebates, and other incentives, such as voluntary patient assistance, and other allowances that are offered within contracts between the Company and its customers, payors, and other indirect customers relating to the Company’s sale of its products. These reserves, as detailed below, are based on the related sales, and are classified as reductions of accounts receivable, net when the right of offset exists in accordance with Accounting Standards Update ("ASU”) 2013-1, Balance Sheet (Topic 210): Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities, or as a current liability. These estimates take into consideration a range of possible outcomes that are probability-weighted in accordance with the expected value method in ASC 606 for relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the respective underlying contracts.

The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s analyses also contemplated application of the constraint in accordance with the guidance, under which it determined a significant reversal of revenue would not likely occur in a future period for the estimates detailed below as of December 31, 2025 and, therefore, the transaction price was not reduced further during the year ended December 31, 2025. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.

Trade Discounts and Allowances

The Company generally provides customers with discounts, which include incentive fees that are explicitly stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. The reserve for discounts is established in the same period that the related revenue is recognized, together with reductions to accounts receivable, net on the consolidated balance sheets. In addition, the Company compensates its customers for sales order management, data, and distribution services. The Company has determined such services received to date are not distinct from the Company’s sale of products to its customers and, therefore, these payments have been recorded as a reduction of revenue within the statement of operations.

Product Returns

Consistent with industry practice, the Company offers the specialty pharmacies and specialty distributors that are its customers limited product return rights for damaged and expiring product, provided it is within a specified period around the product expiration date as set forth in the applicable individual distribution agreement. The Company estimates the amount of its product sales that may be returned by its customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized, as well as a reduction to accounts receivables, net on the consolidated balance sheets. The Company currently estimates product returns using its own sales information, including its visibility into the inventory remaining in the distribution channel. The Company has an insignificant number of returns to date and believes that returns of its products will continue to be minimal.

Provider Chargebacks and Discounts

Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list prices charged to its customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. The reserve for chargebacks is established in the same period that the related revenue is recognized, resulting in a reduction of product revenue and a reduction to accounts receivable, net on the consolidated balance sheets. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers, and the Company generally issues credits for such amounts within a few weeks of the customer’s notification to the Company of the resale. Chargebacks consist of credits the Company expects to issue for units that remain in the distribution channel at each reporting period end that the Company expects will be sold to qualified healthcare providers and chargebacks that customers have claimed, but for which the Company has not yet issued a payment.

Government Rebates

The Company is subject to discount obligations under state Medicaid programs and Medicare. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue, net and the establishment of a current liability, which is included in accrued expenses on the consolidated balance sheets. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimates of future claims that will be made for product that has been recognized as revenue, but which remains in the distribution channel at the end of each reporting period.

Payor Rebates

The Company contracts with certain private payor organizations, primarily insurance companies and pharmacy benefit managers, for the payment of rebates with respect to utilization of its products. The Company estimates these rebates and records such estimates in the same period the related revenue is recognized, resulting in a reduction of product revenue, net and the establishment of a current liability, which is included in accrued expenses on the consolidated balance sheets.

Other Incentives

Other incentives the Company offers include voluntary patient assistance programs, such as the co-pay assistance program, which are intended to provide financial assistance to qualified commercially insured patients with prescription drug co-payments required by payors. The calculation of the accrual for co-pay assistance is based on an estimate of claims and the cost per claim that the Company expects to receive associated with product that has been recognized as revenue, but remains in the distribution channel at the end of each reporting period. The adjustments are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability, which is included as a component of accrued expenses on the consolidated balance sheets.

License Revenue

The Company also recognizes license revenue under certain of the Company’s sub-license agreements that are within the scope of ASC 606. The terms of these agreements may contain multiple performance obligations, which may include licenses and research and development activities. The Company evaluates these agreements under ASC 606 to determine the distinct performance obligations. Non-refundable, upfront fees that are not contingent on any future performance and require no consequential continuing involvement by the Company, are recognized as revenue when the license term commences and the licensed data, technology or product is delivered. The Company defers recognition of non-refundable upfront license fees if the performance obligations are not satisfied. The Company’s payment terms range between the execution date of the sub-license agreement and 45 days.

Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved.

If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on its relative standalone selling price. The standalone selling price is generally determined based on the prices charged to customers or using expected cost-plus margin. Revenue is recognized by measuring the progress toward complete satisfaction of the performance obligations using an input measure.

Since 2018, the Company has entered into sub-license agreements with certain sub-licensees in territories outside of the United States. These sub-licensing agreements grant certain intellectual property rights and set forth various obligations with respect to actions such as development, pursuit and maintenance of regulatory approvals, commercialization and supply of NERLYNX in the sub-licensees’ respective territories.

License fees under the sub-license agreements include one-time upfront payments when each sub-license agreement was executed and potential additional one-time milestone payments due to the Company upon successful completion of certain performance obligations, such as achieving regulatory approvals or sales target thresholds, and potential double-digit royalties on sales of the licensed product, calculated as a percentage of net sales of the licensed product throughout each sub-licensee’s respective territory. As of December 31, 2025, the total potential milestone payments that would be due to the Company upon achievement of all respective performance obligations under the sub-license agreements is approximately $579.8 million. At this time, the Company cannot estimate if or when these milestone-related performance obligations might be achieved.

Royalty Revenue

For sub-license agreements that are within the scope of ASC 606, the Company recognizes revenue when the related sales occur in accordance with the sales-based royalty exception under ASC 606-10-55-65. Royalty revenue consists of consideration earned related to international sales of NERLYNX made by the Company’s sub-licensees in their respective territories. The Company recognizes royalty revenue when the performance obligations have been satisfied. The Company’s payment terms range between 10 and 60 days.

Royalty Expenses

Royalties incurred in connection with the Company’s license agreement with Pfizer, as disclosed in Note 13–Commitments and Contingencies, are expensed to cost of sales as revenue from product sales is recognized.

Legal Contingencies and Expense

For legal contingencies, the Company accrues a liability for an estimated loss if the potential loss from any claim or legal proceeding is considered probable and the amount can be reasonably estimated. Legal fees and expenses are expensed as incurred based on invoices or estimates provided by legal counsel. The Company periodically evaluates available information, both internal and external, relative to such contingencies and adjusts the accrual as necessary. The Company determines whether a contingency should be disclosed by assessing whether a material loss is deemed reasonably possible. In determining whether a loss should be accrued, the Company evaluates, among other factors, the degree of probability of an unfavorable outcome and the ability to make a reasonable estimate of the amount of the loss (see Note 13-Commitments and Contingencies).

Research and Development Expenses

Research and development (“R&D”) expenses are charged to operations as incurred. The major components of research and development costs include clinical manufacturing costs, clinical trial expenses, consulting and other third-party costs, salaries and employee benefits, stock-based compensation expense, supplies and materials, and allocations of various overhead costs. Clinical trial expenses include, but are not limited to, investigator fees, site costs, comparator drug costs, and clinical research organization (“CRO”) costs. In the normal course of business, the Company contracts with third parties to perform various clinical trial activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variations from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events, the successful enrollment of patients and the completion of portions of the clinical trial or similar conditions. The Company’s accruals for clinical trials are based on estimates of the services received and efforts expended pursuant to contracts with numerous clinical trial sites, cooperative groups and CROs. As actual costs become known, the Company adjusts its accruals in that period.

In instances where the Company enters into agreements with third parties for clinical trials and other consulting activities, upfront amounts are recorded to prepaid expenses and other in the accompanying consolidated balance sheets and expensed as services are performed or as the underlying goods are delivered. If the Company does not expect the services to be rendered or goods to be delivered, any remaining capitalized amounts for non-refundable upfront payments are charged to expense immediately. Amounts due under such arrangements may be either fixed fee or fee for service, and may include upfront payments, monthly payments and payments upon the completion of milestones or receipt of deliverables.

Costs related to the acquisition of technology rights and patents for which development work is still in process are charged to operations as incurred and considered a component of research and development costs.

Stock-Based Compensation

Stock Option Awards

ASC Topic 718, Compensation-Stock Compensation (“ASC 718”) requires the fair value of all share-based payments to employees and non-employees, including grants of stock options, to be recognized in the statement of operations over the requisite service period. Under ASC 718, employee and non-employee option grants are generally valued at the grant date and those valuations do not change once they have been established. The fair value of each option award is estimated on the grant date using the Black-Scholes Option Pricing Method. The Company’s estimate of expected volatility is based on its average volatility using its expected life, or approximately the last six years of publicly traded history. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant valuation. Option forfeitures are estimated when the option is granted to reduce the option expense to be recognized over the life of the award. The estimated forfeiture rate considers historical employee turnover rates stratified into employee pools, actual forfeiture experience and other factors. The option expense is adjusted upon the actual forfeiture of a stock option grant and the Company periodically revises the estimated forfeiture rate in subsequent periods if actual forfeitures differ from those estimates. Due to its limited history of stock option exercises, the Company uses the simplified method to determine the expected life of the option grants. Compensation expense related to modified stock options is measured based on the fair value for the awards as of the modification date. Any incremental compensation expense arising from the excess of the fair value of the awards on the modification date compared to the fair value of the awards immediately before the modification date is recognized at the modification date or ratably over the requisite service period, as appropriate.

Restricted Stock Units

RSUs are valued on the grant date and the fair value of the RSUs is equal to the market price of the Company’s common stock on the grant date. The RSU expense is recognized over the requisite service period. When the requisite service period begins prior to the grant date (because the service inception date occurs prior to the grant date), the Company is required to begin recognizing compensation cost before there is a measurement date (i.e., the grant date). The service inception date is the beginning of the requisite service period. If the service inception date precedes the grant date, accrual of compensation cost for periods before the grant date shall be based on the fair value of the award at the reporting date. In the period in which the grant date occurs, cumulative compensation cost shall be adjusted to reflect the cumulative effect of measuring compensation cost based on fair value at the grant date rather than the fair value previously used at the service inception date (or any subsequent reporting date). RSU forfeitures are estimated when the RSU is granted to reduce the RSU expense to be recognized over the life of the award. The estimated forfeiture rate considers historical employee turnover rates stratified into employee pools, actual forfeiture experience and other factors. The RSU expense is adjusted upon the actual forfeiture of an RSU grant and the Company periodically revises the estimated forfeiture rate in subsequent periods if actual forfeitures differ from those estimates. Compensation expense related to modified RSUs is measured based on the fair value for the awards as of the modification date. Any incremental compensation expense arising from the excess of the fair value of the awards on the modification date compared to the fair value of the awards immediately before the modification date is recognized at the modification date or ratably over the requisite service period, as appropriate.

Warrants

Warrants (see Note 10–Stockholders’ Equity for further details) granted to employees and non-employees are normally valued at the fair value of the instrument on the grant date and are recognized in the statement of operations over the requisite service period. When the requisite service period precedes the grant date and a market condition exists in the warrant, the Company values the warrant using the Monte Carlo Simulation Method. When the terms of the warrant become fixed, the Company values the warrant using the Black-Scholes Option Pricing Method. The Company’s estimate of expected volatility is based on its average volatility using its past nine years of publicly traded history. The risk-free rate for periods within the contractual life of the warrant is based on the U.S. Treasury yield curve in effect at the time of grant valuation. In determining the value of the warrant until the terms are fixed, the Company factors in the probability of the market condition occurring and several possible scenarios. When the requisite service period precedes the grant date and is deemed to be complete, the Company records the fair value of the warrant at the time of issuance as an equity stock-based compensation transaction. The grant date is determined when all pertinent information, such as exercise price and quantity are known.

Income Taxes

The Company follows ASC Topic 740, Income Taxes (“ASC 740”) which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the consolidated financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the consolidated financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.

The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the consolidated financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the consolidated financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. ASC 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. As of December 31, 2025, the Company’s uncertain tax positions include a reserve for its Research and Development credits.

On July 4, 2025, the “One Big Beautiful Bill” was signed into law, which includes significant changes to federal tax law and other regulatory provisions that may impact the Company. As of the date of these financial statements, the Company has evaluated the impact of the changes to Section 174 – Amortization of research and experimental expenditures on the valuation allowance release. The Company intends to deduct the capitalized costs over two years. This deduction reduces the amount of net operating losses being utilized but results in a net zero change to the deferred tax asset balance. In 2025, we released a portion of our valuation allowance related to our deferred tax assets in the amount of $3.8 million, which reduced our net income for the year.

Financial Instruments

The carrying value of financial instruments, such as cash equivalents, accounts receivable and accounts payable, approximate their fair value because of their short-term nature. The carrying value of long-term debt approximates its fair value as the principal amounts outstanding are subject to variable interest rates that are based on market rates that are regularly reset.

Cash and Cash Equivalents

The Company classifies all highly liquid instruments with an original maturity of three months or less as cash equivalents.

Restricted Cash

Restricted cash represents cash held at financial institutions that is pledged as collateral for stand-by letters of credit for office leases. The lease related letters of credit will lapse at the end of the respective lease terms through 2026. At December 31, 2025 and 2024, the Company had restricted cash in the amount of $2.1 million.

Investment Securities

The Company classifies all investment securities (short-term and long-term) as available-for-sale, as the sale of such securities may be required prior to maturity to implement management’s strategies. These securities are carried at fair value, with the unrealized gains and losses, reported as a component of accumulated other comprehensive income in stockholders’ equity until realized. Realized gains and losses from the sale of available-for-sale securities, if any, are determined on a specific identification basis. In accordance with ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, credit losses on available-for-sale securities are reported using an expected loss model and recorded to an allowance. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method. Interest income is recognized when earned.

Assets Measured at Fair Value on a Recurring Basis

ASC Topic 820, Fair Value Measurement (“ASC 820”) provides a single definition of fair value and a common framework for measuring fair value as well as disclosure requirements for fair value measurements used in financial statements. Under ASC 820, fair value is determined based upon the exit price that would be received by a company to sell an asset or paid by a company to transfer a liability in an orderly transaction between market participants, exclusive of any transaction costs. Fair value measurements are determined by either the principal market or the most advantageous market. The principal market is the market with the greatest level of activity and volume for the asset or liability. Absent a principal market to measure fair value, the Company uses the most advantageous market, which is the market from which the Company would receive the highest selling price for the asset or pay the lowest price to settle the liability, after considering transaction costs. However, when using the most advantageous market, transaction costs are only considered to determine which market is the most advantageous and these costs are then excluded when applying a fair value measurement. ASC 820 creates a three-level hierarchy to prioritize the inputs used in the valuation techniques to derive fair values. The basis for fair value measurements for each level within the hierarchy is described below, with Level 1 having the highest priority and Level 3 having the lowest.

Level 1:

Quoted prices in active markets for identical assets or liabilities.

Level 2:

Quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations in which all significant inputs are observable in active markets.

Level 3:

Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

Following are the major categories of assets measured at fair value on a recurring basis as of December 31, 2025 and 2024, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3) (in thousands):

December 31, 2025	*Level 1*		*Level 2*		*Level 3*		*Total*
Cash equivalents	$	5,060	$	18,710	$	—	$	23,770
U.S. Government securities		27,903		14,873		—		42,776
Corporate Bonds		—		6,865		—		6,865
Commercial paper		—		18,252		—		18,252
	$	32,963	$	58,700	$	—	$	91,663

December 31, 2024	*Level 1*		*Level 2*		*Level 3*		*Total*
Cash equivalents	$	16,996	$	38,102	$	—	$	55,098
U.S. Government securities		17,568		8,617		—		26,185
Commercial paper		—		5,561		—		5,561
Totals	$	34,564	$	52,280	$	—	$	86,844

The Company’s investments in commercial paper and U.S. government securities are exposed to price fluctuations. The fair value measurements for commercial paper, corporate bonds and U.S. government securities are based upon the quoted prices of identical and similar items in active markets multiplied by the number of securities owned.

The following tables summarize the Company’s short-term investments (in thousands):

	*Maturity*	*Amortized*		*Unrealized*					*Estimated*
December 31, 2025	*(in years)*	*Cost*		*Gains*		*Losses*			*Fair Value*
Cash equivalents		$	23,772	$	—	$	(2	)	$	23,770
U.S. Government securities	Less than 1		42,739		37		—			42,776
Corporate Bonds	Less than 1		6,866		1		(2	)		6,865
Commercial paper	Less than 1		18,250		3		(1	)	$	18,252
Totals		$	91,627	$	41	$	(5	)	$	91,663

	*Maturity*	*Amortized*		*Unrealized*					*Estimated*
December 31, 2024	*(in years)*	*Cost*		*Gains*		*Losses*			*Fair Value*
Cash equivalents		$	55,096	$	4	$	(2	)	$	55,098
U.S. Government securities	Less than 1		26,186	$	7	$	(8	)		26,185
Commercial paper	Less than 1		5,556		5		—			5,561
Totals		$	86,838	$	16	$	(10	)	$	86,844

Concentration of Risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, principally consist of cash and cash equivalents, marketable securities, and accounts receivable, net. The Company’s cash and cash equivalents and restricted cash in excess of the Federal Deposit Insurance Corporation and the Securities Investor Protection Corporation insured limits at December 31, 2025, were approximately $36.6 million. The Company does not believe it is exposed to any significant credit risk due to the quality nature of the financial instruments in which the money is held. Pursuant to the Company’s internal investment policy, investments must be rated A-1/P-1 or better by Standard and Poor’s Rating Service and Moody’s Investors Service at the time of purchase.

The Company sells its products in the United States primarily through specialty pharmacies and specialty distributors. Therefore, wholesale distributors and large pharmacy chains account for a large portion of its accounts receivables, net and product revenues, net. The creditworthiness of its customers is continuously monitored, and the Company has internal policies regarding customer credit limits. The Company estimates an allowance for credit loss primarily based on the creditworthiness of its customers, historical payment patterns, aging of receivable balances and general economic conditions. The Company recorded $0.4 million credit loss recovery in the year ended December 31, 2025, and $0.5 million in the year ended December 31, 2024.

As of December 31, 2025 and 2024, accounts receivable from individual customers with balances due in excess of 10% of total accounts receivable totaled $38.9 million and $22.9 million, respectively.

The Company’s success depends on its ability to successfully commercialize NERLYNX. The Company currently has a single product and limited commercial sales experience, which makes it difficult to evaluate its current business, predict its future prospects and forecast financial performance and growth. The Company has invested a significant portion of its efforts and financial resources in the development and commercialization of its lead product, NERLYNX, and expects NERLYNX to constitute the vast majority of product revenue for the foreseeable future.

The Company relies exclusively on third parties to formulate and manufacture NERLYNX and its drug candidates. The commercialization of NERLYNX and any other drug candidates, if approved, could be stopped, delayed or made less profitable if those third parties fail to provide sufficient quantities of product or fail to do so at acceptable quality levels or prices. The Company has no experience in drug formulation or manufacturing and does not intend to establish its own manufacturing facilities. The Company lacks the resources and expertise to formulate or manufacture NERLYNX and other drug candidates. While the drug candidates were developed by Pfizer, both the drug substance and drug product are manufactured by third-party contractors. The Company is using the same third-party contractors to manufacture, supply, store and distribute drug supplies for clinical trials and the commercialization of NERLYNX. If the Company is unable to continue its relationships with one or more of these third-party contractors, it could experience delays in the development or commercialization efforts as it locates and qualifies new manufacturers. The Company intends to rely on one or more third-party contractors to manufacture the commercial supply of drugs.

Inventory

The Company values its inventories at the lower of cost and estimated net realizable value. The Company determines the cost of its inventories, which includes amounts related to materials and manufacturing overhead, on a first-in, first-out basis and uses standard costing. The Company performs an assessment of the recoverability of capitalized inventory during each reporting period, and it writes down any excess and obsolete inventories to their estimated realizable value in the period in which the impairment is first identified. Such impairment charges, should they occur, are recorded within the cost of sales in the consolidated statements of operations. The determination of whether inventory costs will be realizable requires estimates by management. If actual market conditions are less favorable than projected by management, additional write-downs of inventory may be required, which would be recorded as a cost of sales in the consolidated statements of operations.

The Company capitalizes inventory costs associated with the Company’s products after regulatory approval, if any, when, based on management’s judgment, future commercialization is considered probable, and the future economic benefit is expected to be realized. Inventory that can be used in either the production of clinical or commercial product is recorded as research and development expense when selected for use in a clinical trial. Starter kits, provided to patients prior to insurance approval, are expensed by the Company to selling, general and administrative expense as incurred. Of the total inventory amounts noted below, approximately $4.5 million and $1.2 million was located at contract manufacturing organizations in Europe as of December 31, 2025 and 2024, respectively.

The Company’s inventory balances are as follows:

	*December 31, 2025*		*December 31, 2024*
Raw materials	$	3,212	$	7,183
Work-in-process (materials, labor and overhead)		1,343		758
Finished goods (materials, labor and overhead)		960		783
Total inventories	$	5,515	$	8,724

Property and Equipment, Net

Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the useful lives of the assets, which is generally three years for computer hardware and software, three years for phone equipment, and seven years for furniture and fixtures. Leasehold improvements are amortized using the straight-line method over the lesser of the useful life or the lease term. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.

The Company reviews its long-lived assets used in operations for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable, as required by ASC Topic 360, Property, Plant, and Equipment (“ASC 360”). The Company performs a recoverability test by comparing the sum of the estimated undiscounted cash flows over the life of the asset to its carrying value on the consolidated balance sheet. If the undiscounted cash flows used in the recoverability test are less than the carrying value, the Company would then determine the fair value of the long-lived asset and recognize an impairment loss for the amount in excess of the carrying value. No material impairments were recorded during the years ended December 31, 2025 and 2024.

Leases

ASC Topic 842, Leases, as adopted in the first quarter of 2019, requires lessees to recognize most leases on the balance sheet with a corresponding right-of-use asset (“ROU asset”). ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The assets and lease liabilities are recognized at the lease commencement date based on the estimated present value of fixed lease payments over the lease term. ROU assets are evaluated for impairment using the long-lived assets impairment guidance, as required by ASC 360. A significant indication of impairment of an ROU asset would include a change in the extent or manner in which the asset is being used. The Company must make assumptions that underlie the most significant and subjective estimates in determining whether any impairment exists. Those estimates, and the underlying assumptions, include estimates of future cash flow utilizing market lease rates and determination of fair value. If an ROU asset related to an operating lease is impaired, the carrying value of the ROU asset post-impairment should be amortized on a straight-line basis through the earlier of the end of the useful life of the ROU asset or the end of the lease term. Post impairment, a lessee must calculate the amortization of the ROU asset and interest expense on the lease liability separately, although the sum of the two continues to be presented as a single lease cost. If a lease is planned to be abandoned with no intention of subleasing, the ROU asset should be assessed for impairment.

Leases are classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. For additional information, see Note 6–Leases.

The Company leases office space and copy machines, all of which are operating leases. Most leases include the option to renew, and the exercise of the renewal options is at the Company’s sole discretion. Options to extend or terminate a lease are considered in the lease term to the extent that the option is reasonably certain of exercise. The leases do not include options to purchase the leased property. The depreciable life of assets and leasehold improvements is limited by the expected lease term. Covenants imposed by the leases include letters of credit required to be obtained by the lessee.

The Company is required to remeasure the lease liability and make an adjustment in the following instances:

• The term of the lease has been modified or there has been a change in the Company’s assessment of a purchase option being exercised, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate;

• A lease contract is modified, and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate; and

• The lease payments are adjusted due to changes in the index or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using the initial discount rate.

The incremental borrowing rate (“IBR”) represents the rate of interest the Company would expect to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. As the implicit rate on the Company’s leases are not readily determinable, the Company uses its IBR based on the information available at the commencement date in determining the present value of lease payments. The Company’s average IBR for existing leases as of December 31, 2025 was 12.2%.

The Company decided to cease the use of a portion of its leased office space in 2023. In connection with the decreased need for the right to use the ROU asset, the Company entered into a sublease for the underlying asset, in which the sublease income is less than the original lease payments, indicating impairment. In performing the recoverability test on the effective date, the undiscounted future estimated cash flows and carrying value were identified for the subleased portion of the leased building, as an individual asset group, defined under ASC 360. A reduction to the carrying value of the ROU asset of approximately $0.6 million was recorded, representing the fair value amount in excess of the carrying value, with a corresponding impairment charge recorded as selling, general and administration expense, in the consolidated statements of operations for the year ended December 31, 2023.

License Fees and Intangible Assets

The Company expenses amounts paid to acquire licenses associated with products under development when the ultimate recoverability of the amounts paid is uncertain and the technology has no alternative future use when acquired. Acquisitions of technology licenses are charged to expense or capitalized based upon the asset achieving technological feasibility in accordance with management’s assessment regarding the ultimate recoverability of the amounts paid and the potential for alternative future use. The Company has determined that technological feasibility for its drug candidates is reached when the requisite regulatory approvals are obtained to make the product available for sale. The Company capitalizes technology licenses upon reaching technological feasibility.

The Company maintains definite-lived intangible assets related to the license agreement with Pfizer. These assets are amortized over their remaining useful lives, which are estimated based on the shorter of the remaining patent life or the estimated useful life of the underlying product. Intangible assets are amortized using the economic consumption method if anticipated future revenues can be reasonably estimated. The straight-line method is used when future revenues cannot be reasonably estimated. Amortization costs are recorded as part of cost of sales.

The Company assesses its intangible assets for impairment if indicators are present or changes in circumstance suggest that impairment may exist. Events that could result in an impairment, or trigger an interim impairment assessment, include the receipt of additional clinical or non-clinical data regarding one of the Company’s drug candidates or a potentially competitive drug candidate, changes in the clinical development program for a drug candidate, or new information regarding potential sales of the drug. If impairment indicators are present or changes in circumstance suggest that impairment may exist, the Company performs a recoverability test by comparing the sum of the estimated undiscounted cash flows of each asset group to its carrying value on the consolidated balance sheet. If the undiscounted cash flows used in the recoverability test are less than the carrying value, the Company would determine the fair value of the intangible asset and recognize an impairment loss if the carrying value of the intangible asset exceeds its fair value. In connection with the FDA approval of NERLYNX in July 2017, the Company triggered a one-time milestone payment pursuant to its license agreement with Pfizer. In June 2020, the Company entered into a letter agreement with Pfizer relating to the method of payment associated with a milestone payment under the Company’s license agreement with Pfizer (see Note 13–Commitments and Contingencies). The Company capitalized the milestone payments as an intangible asset and is amortizing the asset to cost of sales on a straight-line basis over the estimated useful life of the licensed patent through 2030. In addition, the Company reached a commercial milestone by achieving aggregate worldwide net sales of $250 million in calendar year 2022, resulting in a payable to Pfizer of $12.5 million as of December 31, 2022. The Company capitalized this milestone as an intangible asset and accrued in-licensed rights on the accompanying consolidated balance sheets and payment was made in the first quarter of 2023. The Company recorded amortization expense related to its intangible assets of $9.7 million, $9.7 million, and $8.0 million for the years ended December 31, 2025, 2024 and 2023, respectively. As of December 31, 2025, estimated future amortization expense related to the Company’s intangible asset was approximately $9.7 million for each year from 2026 through 2029, and $2.4 million for 2030.

Accounting Pronouncements Adopted During the Current Year

ASU 2023-09, Improvements to Income Tax Disclosures

On December 14, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (“ASU 2023-09”). ASU 2023-09 amends ASC 740, Income Taxes to expand income tax disclosures and requires that the Company disclose (i) the income tax rate reconciliation using both percentages and reporting currency amounts; (ii) specific categories within the income tax rate reconciliation; (iii) additional information for reconciling items that meet a quantitative threshold; (iv) the composition of state and local income taxes by jurisdiction; and (v) the amount of income taxes paid disaggregated by jurisdiction. The Company adopted ASU 2023-09 for the year ended December 31, 2025 on a prospective basis. Accordingly, the expanded disclosures are provided for the year ended December 31, 2025, while prior period disclosures have not been retroactively adjusted and continue to be presented under the previous disclosure requirements. As this update only impacts disclosures, its adoption did not have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. See Note 12 Income Taxes for additional information.

Recently Issued Accounting Standards

In November 2024, the FASB issued ASU 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures: The ASU requires more detailed information about specified categories of expenses included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this ASU on its consolidated financial statements and related disclosures.

Note 10 - Stockholders' Equity - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Exercised, shares (in shares)	(55,882)	(64,118)	0
The 2011 and 2017 Plans [Member]
Balance, shares (in shares)	4,051,928
Balance, weighted average exercise price (in dollars per share)	$ 33.8
Granted, shares (in shares)	492,514
Granted, weighted average exercise price (in dollars per share)	$ 2.78
Foreited (in shares)	(84,954)
Forfeited, weighted average exercise price (in dollars per share)	$ 3.57
Exercised, shares (in shares)	(55,882)
Exercised, weighted average exercise price (in dollars per share)	$ 2.33
Expired, shares (in shares)	(1,186,317)
Expired, weighted average exercise price (in dollars per share)	$ 67.35
Balance, shares (in shares)	3,217,289	4,051,928
Outstanding, weighted average exercise price (in dollars per share)	$ 16.13	$ 33.8
Outstanding, weighted average remaining contractual term (Year)	5 years 4 months 24 days
Outstanding, aggregate intrinsic value	$ 3,609
Vested and expected to vest, shares (in shares)	3,217,289
Vested and expected to vest, weighted average exercise price (in dollars per share)	$ 16.13
Vested and expected to vest, weighted average remaining contractual term (Year)	5 years 4 months 24 days
Vested and expected to vest, aggregate intrinsic value	$ 3,609
Exercisable, shares (in shares)	2,811,562
Exercisable, weighted average exercise price (in dollars per share)	$ 17.95
Exercisable, weighted average remaining contractual term (Year)	4 years 10 months 24 days
Exercisable, aggregate intrinsic value	$ 2,593

Note 11 - 401(k) Savings Plan

12 Months Ended

Dec. 31, 2025

Compensation and Employee Benefit Plans [Text Block]

Note 11—401(k) Savings Plan

During 2012, the Company adopted a 401(k) savings plan for the benefit of its employees. The Company is required to make matching contributions to the 401(k) plan equal to 100% of the first 3% of wages deferred by each participating employee and 50% on the next 2% of wages deferred by each participating employee. The Company incurred expenses for employer matching contributions of approximately $1.6 million for each of the years ended December 31, 2025, 2024 and 2023.

Note 12 - Income Taxes - Schedule of Income Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Domestic	$ 35,782	$ 24,100	$ 22,674
Foreign	0	0	0
Income Before Income Taxes	$ 35,782	$ 24,100	$ 22,674

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Cybersecurity Risk Management, Strategy, and Governance [Line Items]

Note 2 - Significant Accounting Policies - Assets Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Fair Value, Recurring [Member]
Totals	$ 91,663	$ 86,844
Fair Value, Recurring [Member] \| US Government Agencies Debt Securities [Member]
Investments	42,776	26,185
Fair Value, Recurring [Member] \| Corporate Bond Securities [Member]
Investments	6,865
Fair Value, Recurring [Member] \| Commercial Paper [Member]
Investments	18,252	5,561
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Totals	32,963	34,564
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| US Government Agencies Debt Securities [Member]
Investments	27,903	17,568
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| Corporate Bond Securities [Member]
Investments	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member] \| Commercial Paper [Member]
Investments	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Totals	58,700	52,280
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| US Government Agencies Debt Securities [Member]
Investments	14,873	8,617
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Corporate Bond Securities [Member]
Investments	6,865
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member] \| Commercial Paper [Member]
Investments	18,252	5,561
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Totals	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| US Government Agencies Debt Securities [Member]
Investments	0	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| Corporate Bond Securities [Member]
Investments	0
Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member] \| Commercial Paper [Member]
Investments	0	0
Cash Equivalents [Member]
Cash equivalents	23,770	55,098
Cash Equivalents [Member] \| Fair Value, Recurring [Member]
Cash equivalents	23,770	55,098
Cash Equivalents [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Cash equivalents	5,060	16,996
Cash Equivalents [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Cash equivalents	18,710	38,102
Cash Equivalents [Member] \| Fair Value, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Cash equivalents	$ 0	$ 0

Note 5 - Property and Equipment (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Depreciation	$ 0.4	$ 0.4	$ 0.4

Note 8 - Accrued Expenses - Composition of Current and Long-term Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Accrued royalties	$ 15,858	$ 10,169
Accrued CRO services	3,793	1,035
Accrued variable consideration	14,215	10,829
Accrued bonus	8,377	7,976
Accrued compensation	5,797	4,368
Accrued other clinical development	567	935
Accrued professional fees	132	341
Accrued legal fees	990	1,095
Accrued manufacturing costs	93	39
Other	209	111
Total, long-term	50,031	36,898
Accrued other liabilities	0	121
Accrued Liabilities, Noncurrent	0	121
Totals	$ 50,031	$ 37,019

Cybersecurity Risk Management and Strategy Disclosure

12 Months Ended

Dec. 31, 2025

Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]

ITEM 1C.

CYBERSECURITY

Cybersecurity Risk Management and Strategy

We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.

We design and assess our program based on the National Institute of Standards and Technology Cybersecurity Framework (“NIST CSF”). This does not imply that we meet any particular technical standards, specifications or requirements, only that we use the NIST CSF as a guide to help us identify, assess and manage cybersecurity risks relevant to our business.

Our cybersecurity risk management program is integrated into our overall risk management program, and shares common methodologies, reporting channels and governance processes that apply across the risk management program to other legal, compliance, strategic, operational, and financial risk areas.

Key elements of our cybersecurity risk management program include, but are not limited to the following:

•

risk assessments designed to help identify material cybersecurity threats to our critical systems and information;

•

a management team responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls and (3) our response to cybersecurity incidents;

•

the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security processes;

•

cybersecurity awareness training of our employees, including incident response personnel and senior management;

•

a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and

•

a third-party risk management process for key service providers, based on our assessment of their criticality to our operations and respective risk profile.

We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us, including our operations, business strategy, results of operations, or financial condition. We face risks from cybersecurity threats that, if realized, are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition. See “Risk Factors – We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm us.”

Cybersecurity Risk Management Processes Integrated [Flag]

true

Cybersecurity Risk Management Processes Integrated [Text Block]

We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our critical systems and information.

Cybersecurity Risk Management Third Party Engaged [Flag]

true

Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]

true

Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]

false

Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]

Cybersecurity Risk Board of Directors Oversight [Text Block]

Cybersecurity Governance

Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee (the “Committee”) oversight of cybersecurity risks, including oversight of management’s implementation of our cybersecurity risk management program.

The Committee receives periodic reports from management on our cybersecurity risks. In addition, management updates the Committee, where it deems appropriate, regarding any cybersecurity incidents it considers to be potentially significant.

The Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also periodically receives briefings from management on our cyber risk management program. Board members receive presentations on cybersecurity topics from internal security staff or external experts as part of the Board’s continuing education on topics that impact public companies. Our management team, including our Senior Director of Information Technology and Senior Vice President, Quality Assurance, who report to the Chief Financial Officer and Chief Executive Officer, respectively, are primarily responsible for assessing and managing our material risks from cybersecurity threats. The Senior Director of Information Technology and Senior Vice President, Quality Assurance have primary responsibility for our overall cybersecurity risk management program and supervise both our internal technology and quality assurance compliance personnel and our retained external cybersecurity consultants. Our Senior Director of Information Technology has more than 20 years of experience in IT Management, including cybersecurity, and our Senior Vice President, Quality Assurance has more than 20 years of experience in computerized system and IT infrastructure controls, compliance, and risk management.

Our management team takes steps to stay informed about and monitor efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in our information technology environment.

Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]

Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]

Cybersecurity Risk Role of Management [Text Block]

Cybersecurity Risk Management Positions or Committees Responsible [Flag]

true

Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]

true

Note 12 - Income Taxes (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

	*2025*		*2024*		*2023*
Domestic	$	35,782	$	24,100	$	22,674
Foreign		—		—		—
Income Before Income Taxes	$	35,782	$	24,100	$	22,674

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	*2025*		*2024*			*2023*
Current:
Federal	$	—	$	—		$	—
State		1,247		722			905
Foreign		179		175			178
		1,426		897			1,083
Deferred:
Federal		3,052		(6,632	)		—
State		193		(443	)		—
		3,245		(7,075	)		—
Total	$	4,671	$	(6,178	)	$	1,083

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	*2025*
	*Amount*			*Percentage*
U.S. federal statutory income tax		7,514			21.0	%
State and local income taxes, net of federal income tax effect (1)		1,238			3.5	%
Foreign tax effects		179			0.5	%
Tax credits		(1,280	)		-3.6	%
Change in valuation allowance		(18,639	)		-52.1	%
Non-taxable or non-deductible items
SBC Options		14,619			40.9	%
Section 162(m)		777			2.2	%
Other nontaxable or nondeductible items		243			0.7	%
Other		20			0.1	%
Income tax expense		4,671			13.1	%

	2024			2023
Tax computed at the federal statutory rate	$	5,061		$	4,488
State taxes		744			1,312
Foreign taxes		175			178
Permanent items		12,946			4,837
R&D credits		(1,532	)		(1,806	)
Prior year adjustment		1,697			(1,715	)
Change in valuation allowance		(25,269	)		(6,211	)
Total provision	$	(6,178	)	$	1,083

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	*2025*			*2024*			*2023*
Deferred tax assets:
Net operating loss carryforwards	$	230,018		$	232,184		$	240,960
Business credit carryforwards		64,968			63,175			62,051
Compensation		13,104			26,081			37,946
Sec 174 R&D expenses		14,505			23,933			19,882
Accrued expenses		139			90			261
Carryforward of disallowed interest		—			—			1,477
Accrued legal verdict		—			—			1,976
Other deferred tax assets		5,718			4,745			4,231
Lease liabilities		1,530			1,764			3,034
Gross deferred tax assets		329,982			351,972			371,818
Valuation allowance		(324,787	)		(343,482	)		(368,751	)
Net deferred tax assets		5,195			8,490			3,067
Deferred tax liabilities:
Other deferred tax liabilities		—			(70	)		(149	)
Right of use assets		(1,365	)		(1,148	)		(1,997	)
Inventory		—			(197	)		(921	)
Total deferred tax liabilities		(1,365	)		(1,415	)		(3,067	)
Net deferred tax assets (liability)	$	3,830		$	7,075		$	—

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]

	*2025*			*2024*			*2023*
Unrecognized tax benefits - January 1	$	3,045		$	2,811		$	2,522
Gross decreases - tax positions in prior period		(50	)		(143	)		(163	)
Gross increases - tax positions in a current period		403			377			452
Unrecognized tax benefits - December 31	$	3,398		$	3,045		$	2,811

Schedule of Cash Taxes Paid [Table Text Block]

	*2025*
Federal income taxes paid (net of refunds)		—
State income taxes paid (net of refunds)		1,092
Foreign income taxes paid (net of refunds)		179

Total income taxes paid (net of refunds)		1,271

State	*2025*
Alabama		172,000
California		181,700
Indiana		199,000
Kentucky		181,400
New York		77,800
Pennsylvania		121,600

Foreign	*2025*
South Korea		179,120

Note 2 - Significant Accounting Policies - Inventory Balance (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Raw materials	$ 3,212	$ 7,183
Work-in-process (materials, labor and overhead)	1,343	758
Finished goods (materials, labor and overhead)	960	783
Total inventories	$ 5,515	$ 8,724

Note 10 - Stockholders' Equity (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	*2025*			*2024*
Dividend yield		0.0	%		0.0	%
Expected volatility		81.5	%		85.8	%
Risk-free interest rate		4.4	%		4.1	%
Expected life in years		5.55			5.55

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	*For the Year Ended*
	*December 31,*
	*2025*		*2024*		*2023*
Stock-based compensation:
Options:
Selling, general, and administrative	$	1,036	$	1,625	$	2,510
Research and development		170		290		611
Restricted stock units:
Selling, general, and administrative		3,247		3,941		4,398
Research and development		2,491		2,389		2,728
Total stock-based compensation expense	$	6,944	$	8,245	$	10,247

Share-Based Payment Arrangement, Activity [Table Text Block]

	*Shares*			*Weighted Average Exercise Price*		*Weighted Average Remaining Contractual Term (years)*		*Aggregate Intrinsic Value (in thousands)*
Outstanding at December 31, 2024		4,051,928		$	33.80
Granted		492,514			2.78
(Forfeited)		(84,954	)		3.57
(Exercised)		(55,882	)		2.33
(Expired)		(1,186,317	)		67.35
Outstanding at December 31, 2025		3,217,289		$	16.13		5.4	$	3,609
Vested and expected to vest at December 31, 2025		3,217,289		$	16.13		5.4	$	3,609
Exercisable		2,811,562		$	17.95		4.9	$	2,593

Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]

	*Shares*			*Weighted Average Grant-Date Fair Value*
Nonvested shares at December 31, 2024		1,289,449		$	5.14
Granted		1,430,211		$	3.36
(Forfeited)		(138,380	)	$	4.03
(Vested)		(1,246,307	)	$	4.57
Nonvested shares at December 31, 2025		1,334,973		$	3.88

Note 9 - Debt - Schedule of Long Term Debt (Details) (Parentheticals) $ in Millions	12 Months Ended
	Dec. 31, 2025 USD ($)
Exit payment	$ 2

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Operating activities:
Net income	$ 31,111	$ 30,278	$ 21,591
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	10,938	11,524	11,519
Stock-based compensation	6,944	8,245	10,247
Deferred income taxes	3,245	(7,075)	(0)
Provision for credit loss recovery	(362)	(519)	881
Loss on disposal of property and equipment	4	0	0
Loss on impairment of asset	0	0	625
Changes in operating assets and liabilities:
Accounts receivable, net	(21,281)	16,345	(8,368)
Inventory, net	3,209	(1,644)	(2,554)
Prepaid expenses and other	(325)	1,000	820
Other current assets	(165)	821	1,517
Accounts payable	(453)	(1,380)	449
Operating lease assets and liabilities, net	(1,805)	(1,587)	(1,195)
Accrued expenses and other	13,154	(15,823)	(7,583)
Post-marketing commitment liability	(2,412)	(1,267)	(940)
Net cash provided by operating activities	41,802	38,918	27,009
Investing activities:
Purchase of property and equipment	(71)	(56)	(140)
Purchase of available-for-sale securities	(108,141)	(76,230)	(23,813)
Maturity of available-for-sale securities	72,024	55,848	17,328
Purchase of intangible assets	0	0	(12,500)
Net cash used in investing activities	(36,188)	(20,438)	(19,125)
Financing activities:
Net proceeds from shares issued under employee stock plans	130	150	0
Payment of debt	(44,440)	(33,330)	0
Payment of exit costs	(888)	(666)	0
Net cash used in financing activities	(45,198)	(33,846)	0
Net (decrease) increase in cash, cash equivalents and restricted cash	(39,584)	(15,366)	7,884
Cash, cash equivalents and restricted cash, beginning of period	71,310	86,676	78,792
Cash, cash equivalents and restricted cash, end of period	31,726	71,310	86,676
Supplemental disclosures of non-cash investing and financing activities:
Property and equipment purchases in accounts payable	5	0	26
Supplemental disclosure of cash flow information:
Interest paid	5,818	10,769	11,628
Income taxes paid	$ 1,524	$ 1,218	$ 737

Note 7 - Intangible Assets (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Finite-Lived Intangible Assets [Table Text Block]

	*December 31, 2025*			*December 31, 2024*
Acquired and in-licensed rights	$	102,500		$	102,500
Less: accumulated amortization		(61,108	)		(51,369	)
Total intangible assets, net	$	41,392		$	51,131

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

2026		9,739
2027		9,739
2028		9,739
2029		9,739
2030		2,436
Totals	$	41,392

Note 1 - Business and Basis of Presentation (Details Textual) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)	Jul. 18, 2014 USD ($)
Number of Subsidiaries	1
Upfront License Fee				$ 7,000
Milestone Payments Maximum Amount	$ 102,500			$ 287,300	$ 187,500
Net Income (Loss) Attributable to Parent	31,111	$ 30,278	$ 21,591
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	41,802	$ 38,918	$ 27,009
Cash, Cash Equivalents, and Marketable Securities	$ 97,500

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(k)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3A
-Subparagraph (24)(d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 9
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479343/105-10-65-9

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 17
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480336/718-10-65-17

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (f)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481538/470-20-65-4

Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Net income	$ 31,111	$ 30,278	$ 21,591
Other comprehensive income:
Unrealized gain (loss) on available-for-sale securities, net of tax of $0	30	10	(4)
Comprehensive income	$ 31,141	$ 30,288	$ 21,587

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Note 6 - Leases (Tables)

12 Months Ended

Dec. 31, 2025

Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]

	*Amount*
2026		1,913
2027		1,248
2028		1,292
2029		1,338
2030		1,385
2031		951
Total minimum lease payments	$	8,127
Less: imputed interest		(2,104	)
Total lease liabilities	$	6,023

Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]

	*Amount*
2026		81
Total	$	81

Lessee, Operating Leases Related To Supplemental Cash Flow Information [Table Text Block]

Supplemental cash flow information related to leases for the twelve months ended December 31, 2025:
Operating cash flows used for operating leases (in thousands)	$	6,469
Right-of-use assets obtained in exchange for new operating lease liabilities		4,123
Weighted-average remaining lease term (in years)		4.7
Weighted average discount rate		12.2	%

Note 6 - Leases

12 Months Ended

Dec. 31, 2025

Lessee, Operating Leases [Text Block]

Note 6—Leases

In December 2011, the Company entered into a non-cancelable operating lease for office space in Los Angeles, California, which was subsequently amended in November 2012, December 2013, March 2014, July 2015 and December 2017. The initial term of the lease was for seven years and commenced on December 10, 2011. As amended, the Company rents approximately 65,656 square feet. The term of the lease runs until March 2026. In July 2025, the Company executed an additional amendment to its office space in Los Angeles, California to surrender certain suites effective March 31, 2026 and extend the lease term for the remaining 26,700 rentable square feet on the 17th floor for an additional five years and five months through August 31, 2031. Base rent escalates annually and is abated from April 2026 through August 2026. Lease payments also include variable charges for the Company’s proportionate share of building operating expenses and real estate taxes based on a 2026 base year. The Company has the option to renew such lease for an additional five year term. Management determined that the renewal option is not reasonably certain to occur. The Company accounted for this amendment as a lease modification. There was no change in the lease classification as a result of this modification and the Company continues to recognize such a lease as an operating lease. The Company remeasured its ROU assets and operating lease liabilities using an updated incremental borrowing rate. The change in ROU assets and operating lease liabilities related to this lease modification amounted to $4.1 million.

In June 2012, the Company entered into a long-term lease agreement for office space in South San Francisco, California, which was subsequently amended in May 2014 and July 2015. As amended, the Company rents approximately 29,470 square feet. The term of this lease runs until March 2026, with the option to extend for an additional five-year term, and rents payable by the Company increase approximately 3% per year. The Company provided the landlord an automatically renewable stand-by letter of credit in the amount of $1.1 million. The stand-by letter of credit is collateralized by a high-yield savings account, which is classified as restricted cash, current on the accompanying consolidated balance sheets.

The Company also leases copier equipment for use in the office spaces. Components of copier lease expense include both fixed and variable lease expenses.

Total rent expense for the years ended December 31, 2025, 2024 and 2023 was approximately $4.5 million, $4.9 million and $4.9 million, respectively. For purposes of determining straight-line rent expense, the lease term is calculated from the date the Company first takes possession of the facility, including any periods of free rent and any renewal option periods that the Company is reasonably certain of exercising. The Company’s office leases generally have contractually specified minimum rent and annual rent increases that are included in the measurement of the ROU asset and related lease liability. Additionally, under these lease arrangements, the Company may be required to pay directly, or reimburse the lessors, for real estate taxes, insurance, utilities, maintenance and other operating costs. Such amounts are generally variable and therefore not included in the measurement of the ROU asset and related lease liability but are instead recognized as variable lease expense in selling, general and administrative costs in the consolidated statements of operations when they are incurred. Variable lease payments not included in the lease liability were $0.5 million and $0.7 million for the years ended December 31, 2025 and 2024, respectively.

The future minimum lease payments under ASC 842 as of December 31, 2025 were as follows (in thousands):

	*Amount*
2026		1,913
2027		1,248
2028		1,292
2029		1,338
2030		1,385
2031		951
Total minimum lease payments	$	8,127
Less: imputed interest		(2,104	)
Total lease liabilities	$	6,023

In February 2019, the Company entered into a long-term sublease agreement for 12,429 square feet of the office space in Los Angeles, California. The term of the lease ran until March 2026 and rent amounts payable to the Company increased approximately 3% per year. The February 2019 sublease was terminated in December 2024. As a result, the Company received $0.7 million, which approximated the sublease rental payments on the remaining lease term. In March 2025, the Company signed another sublease agreement for the 12,429 square feet of office space with a sublease commencement date of April 1, 2025.

In August 2023, the Company entered into a long-term sublease agreement for 13,916 square feet of the office space in Los Angeles, California, which commenced in November 2023. The term of the lease runs until March 2026 and the rent amounts payable to the Company increase approximately 3% per year. The Company has recorded sublease income in other income (expenses) in the condensed consolidated statements of operations since November 2023.

The Company recorded operating sublease income of $0.7 million and $1.4 million for the years ended December 31, 2025 and 2024, respectively, in other income (expenses) in the consolidated statements of operations.

The future minimum lease payments to be received as of December 31, 2025 were as follows (in thousands):

	*Amount*
2026		81
Total	$	81

Supplemental cash flow information related to leases for the year ended December 31, 2025:

Supplemental cash flow information related to leases for the twelve months ended December 31, 2025:
Operating cash flows used for operating leases (in thousands)	$	6,469
Right-of-use assets obtained in exchange for new operating lease liabilities		4,123
Weighted-average remaining lease term (in years)		4.7
Weighted average discount rate		12.2	%

Note 12 - Income Taxes - Schedule of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Federal	$ 0	$ 0	$ 0
State	1,247	722	905
Foreign	179	175	178
Total current	1,426	897	1,083
Federal	3,052	(6,632)	0
State	193	(443)	0
Total deferred	3,245	(7,075)	(0)
Total	$ 4,671	$ (6,178)	$ 1,083

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-21

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Note 6 - Leases (Details Textual) $ in Thousands	1 Months Ended					12 Months Ended
Note 6 - Leases (Details Textual) $ in Thousands	Jul. 31, 2025 USD ($) ft²	Dec. 31, 2024 USD ($)	Aug. 31, 2023 ft²	Feb. 28, 2019 ft²	Jun. 30, 2012 USD ($) ft²	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Apr. 01, 2025 ft²	Dec. 31, 2011 ft²
Increase (Decrease) in Operating Lease Assets and Liabilities, Net						$ 1,805	$ 1,587	$ 1,195
Operating Lease, Expense						4,500	4,900	$ 4,900
Other Nonoperating Income (Expense) [Member]
Sublease Income						700	1,400
CALIFORNIA
Percentage of Annual Rent Increment			3.00%	3.00%
Sublease Income						$ 500	$ 700
Area of Subleased Property (Square Foot) \| ft²			13,916	12,429					12,429
Lease Agreement One [Member]
Area of Leased Property (Square Foot) \| ft²	26,700									65,656
Lessee, Operating Lease, Renewal Term (Year)	5 years 5 months
Lease Option To Extend Term (Year)	5 years
Increase (Decrease) in Operating Lease Assets and Liabilities, Net	$ 4,100
Sublease Income		$ 700
Lease Agreement Two [Member]
Area of Leased Property (Square Foot) \| ft²					29,470
Lease Option To Extend Term (Year)					5 years
Percentage of Annual Rent Increment					3.00%
Letters of Credit Outstanding, Amount					$ 1,100

Note 5 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Property, Plant and Equipment, Gross	$ 4,785	$ 8,383
Less: accumulated depreciation	(4,598)	(7,868)
Property and equipment, net	187	515
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	2,549	3,779
Computer Equipment [Member]
Property, Plant and Equipment, Gross	761	2,150
Telephone Equipment [Member]
Property, Plant and Equipment, Gross	0	95
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross	$ 1,475	$ 2,359

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Allowance for credit loss	$ 0	$ 362
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	50,408,023	49,105,834
Common stock, shares outstanding (in shares)	50,408,023	49,105,834

Note 7 - Intangible Assets

12 Months Ended

Dec. 31, 2025

Intangible Assets Disclosure [Text Block]

Note 7—Intangible Assets

Intangible assets consisted of the following at December 31 (in thousands):

	*December 31, 2025*			*December 31, 2024*
Acquired and in-licensed rights	$	102,500		$	102,500
Less: accumulated amortization		(61,108	)		(51,369	)
Total intangible assets, net	$	41,392		$	51,131

Estimated future intangible amortization expense as of December 31, 2025 is as follows (in thousands):

2026		9,739
2027		9,739
2028		9,739
2029		9,739
2030		2,436
Totals	$	41,392

Note 3 - Accounts Receivable, Net (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Accounts Receivable [Table Text Block]

	*December 31, 2025*		*December 31, 2024*
Trade accounts receivable	$	38,146	$	26,362
Royalty revenue receivable		15,508		6,011
Total accounts receivable	$	53,654	$	32,373

Allowance for credit losses		—		(362	)
Total accounts receivable, net	$	53,654	$	32,011

Note 1 - Business and Basis of Presentation

12 Months Ended

Dec. 31, 2025

Business Description and Basis of Presentation [Text Block]

Note 1—Business and Basis of Presentation

Puma Biotechnology, Inc., (the “Company”) is a biopharmaceutical company based in Los Angeles, California that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. The Company is currently commercializing NERLYNX®, an oral version of neratinib (“NERLYNX”), for the treatment of HER2-positive breast cancer. Additionally, the Company in-licensed, and is responsible for global development and commercialization of, alisertib. Alisertib is a selective, small molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells dependent on Aurora Kinase. The Company believes alisertib has potential application in the treatment of a range of different cancer types, including hormone receptor-positive breast cancer, triple negative breast cancer and small cell lung cancer.

The Company has one subsidiary, Puma Biotechnology, B.V., a Netherlands company. This subsidiary was established for the purpose of legal representation in the European Union (“EU”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany accounts and transactions have been eliminated.

The accompanying consolidated financial statements of the Company and its subsidiary have been prepared in accordance with generally accepted accounting principles in the United States (“US GAAP”).

The Company has incurred significant operating losses since its inception. While the Company has previously reported net income, the Company cannot assure that it will continue to do so and will need to continue to generate significant revenue to sustain operations and successfully commercialize neratinib. In 2017, the Company received U.S. Food and Drug Administration (“FDA”) approval for its first product, NERLYNX® (neratinib), formerly known as PB272 (neratinib, oral), for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy. Following FDA approval in July 2017, NERLYNX became available by prescription in the United States, and the Company commenced commercialization.

In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

In 2018, the European Commission (“EC”) granted marketing authorization for NERLYNX in the EU for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab-based therapy.

The Company is required to make substantial payments to Pfizer upon the achievement of certain milestones and has contractual obligations for clinical trial contracts.

The Company has entered into other exclusive sub-license agreements with various parties to pursue regulatory approval, if necessary, and commercialize NERLYNX, if approved, in many regions outside the United States, including Europe (excluding Ukraine), Australia, Canada, China, Southeast Asia, Israel, South Korea, Russia and various countries and territories in Central America, South America, Africa and the Middle East. The Company plans to continue to pursue commercialization of NERLYNX in other countries outside the United States, if approved.

In September 2022, the Company entered into an exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (“Takeda”) to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of Aurora Kinase A. Alisertib is an adenosine triphosphate–competitive and reversible inhibitor of Aurora Kinase A and results in disruption of mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on Aurora Kinase A. Alisertib has been tested in clinical trials in patients with metastatic cancers including breast cancer, small cell lung cancer, head and neck cancer, ovarian cancer, peripheral T cell lymphoma and acute myeloid leukemia. Under the terms of the exclusive license agreement, the Company assumed sole responsibility for the global development and commercialization of alisertib. The Company paid Takeda an upfront license fee of $7.0 million in October 2022 and Takeda is eligible to receive potential future milestone payments of up to $287.3 million upon the Company’s achievement of certain regulatory and commercial milestones over the course of the exclusive license agreement, as well as tiered royalty payments for any net sales of alisertib. As of December 31, 2025, no milestones had been accrued as the underlying contingencies were not probable or estimable.

The Company has reported net income of approximately $31.1 million and cash provided by operations of approximately $41.8 million for the year ended December 31, 2025. The Company’s commercialization, research and development or marketing efforts may require funding in addition to the cash and cash equivalents and marketable securities totaling approximately $97.5 million at December 31, 2025. The Company believes that its existing cash and cash equivalents and marketable securities as of December 31, 2025 and proceeds that will become available to the Company through product sales and sub-license payments are sufficient to satisfy its operating cash needs, including amounts due under the Company's Note Purchase Agreement with Athyrium, Opportunities IV Co-Invest 1 LP (“Athyrium”) (see Note 9—Debt), for at least one year after the filing of the Annual Report on Form 10-K in which these financial statements are included. The Company continues to remain dependent, in part, on its ability to obtain sufficient funding to sustain operations and continue to successfully commercialize neratinib in the United States. While the Company has been successful in raising capital in the past, there can be no assurance that it will be able to do so in the future. The Company’s ability to obtain funding may be adversely impacted by uncertain market and economic conditions, including the Company’s success in commercializing neratinib and unfavorable decisions of regulatory authorities or adverse clinical trial results. The outcome of these matters cannot be predicted at this time. Additionally, the terms of the Company’s Note Purchase Agreement place restrictions on the Company’s ability to operate the business and on the Company’s financial flexibility, and the Company may be unable to achieve the revenue necessary to satisfy the minimum revenue and cash balance covenants as specified in the agreement.

Since its inception through December 31, 2025, the Company’s financing has primarily been proceeds from product, royalty, and license revenue, public offerings of its common stock, private equity placements, and various debt instruments.

The Company does not believe that tariffs imposed or proposed to be imposed by the United States, particularly with the EU and China, will have a material impact on our product costs or results of operations. However, shifts in trade policies in the United States and other countries have been rapidly evolving and are difficult to predict. The ultimate impact of any announced or future tariffs will depend on various factors, including what tariffs are ultimately implemented, the timing of implementation and the amount, scope and nature of such tariffs and potential exclusions from the application of those tariffs.

Note 10 - Stockholders' Equity

12 Months Ended

Dec. 31, 2025

Equity [Text Block]

Note 10—Stockholders’ Equity

Common Stock

The Company issued 55,882 and 64,118 shares of common stock upon exercise of stock options for the years ended December 31, 2025 and 2024, respectively. The Company did not issue any shares of common stock in 2023. The Company issued 1,246,307, 1,394,929 and 1,301,127 shares of common stock upon vesting of RSUs during the years ended December 31, 2025, 2024 and 2023, respectively.

Authorized Shares

The Company has 100,000,000 shares of stock authorized for issuance, all of which are common stock, par value $0.0001 per share.

Warrants

In October 2011, the Company issued an anti-dilutive warrant to Alan H. Auerbach, the Company's Founder and Chief Executive Officer. The warrant was issued to provide Mr. Auerbach with the right to maintain ownership of at least 20% of the Company’s common stock in the event that the Company raised capital through the sale of its securities in the future.

In connection with the closing of a public offering in October 2012, the exercise price and number of shares underlying the warrant issued to Mr. Auerbach were established and, accordingly, the final value of the warrant became fixed. Pursuant to the terms of the warrant, Mr. Auerbach may exercise the warrant to acquire 2,116,250 shares of the Company’s common stock at $16 per share until October 4, 2021. On April 1, 2021, the Company's Board of Directors approved an amendment to the terms of the warrant by extending the term until October 4, 2026. The amendment was approved by the Company's stockholders on June 15, 2021.

Stock Options and Restricted Stock Units

The Company’s 2011 Incentive Award Plan (“2011 Plan”), as amended, was adopted by the Company’s Board of Directors on September 15, 2011. Pursuant to the 2011 Plan, the Company may grant incentive stock options and nonqualified stock options, as well as other forms of equity-based compensation. Incentive stock options may be granted only to employees, while consultants, employees, officers and directors are eligible for the grant of nonqualified options under the 2011 Plan. The maximum term of stock options granted under the 2011 Plan is 10 years and the awards generally vest over a three-year period. The exercise price of incentive stock options granted under the 2011 Plan must be at least equal to the fair value of such shares on the date of grant. On April 1, 2021, the Board of Directors adopted an amendment to the 2011 Plan to increase the number of shares of the Company's common stock reserved for issuance thereunder by 2,000,000 shares. The amendment was approved by the Company's stockholders on June 15, 2021. On June 18, 2024, the stockholders of the Company approved an amendment to the Company’s 2011 Plan, increasing the number of authorized shares of the Company’s common stock that may become issuable under the 2011 Plan by 3,000,000 shares and extending the period during which incentive stock options may be granted. As of December 31, 2025, a total of 17,529,412 shares of the Company’s common stock have been reserved for issuance under the 2011 Plan.

All of the options awarded by the Company have been “plain vanilla options” as determined by the SEC Staff Accounting Bulletin 107 - Share Based Payment. As of December 31, 2025, 4,157,795 shares of the Company’s common stock are issuable upon the exercise of outstanding stock options and vesting RSUs granted under the 2011 Plan and 3,668,856 shares of the Company’s common stock are available for future issuance under the 2011 Plan. The fair value of options granted to employees and non-employees was estimated using the Black-Scholes Option Pricing Method (see Note 2–Significant Accounting Policies) with the following weighted-average assumptions used during the years ended December 31:

	*2025*			*2024*
Dividend yield		0.0	%		0.0	%
Expected volatility		81.5	%		85.8	%
Risk-free interest rate		4.4	%		4.1	%
Expected life in years		5.55			5.55

The Company’s 2017 Employment Inducement Incentive Award Plan (“2017 Plan”), as amended, was adopted by the Company’s Board of Directors on April 27, 2017. Pursuant to the 2017 Plan, the Company may grant stock options and RSUs, as well as other forms of equity-based compensation to employees, as an inducement to join the Company. The maximum term of stock options granted under the 2017 Plan is 10 years and the awards generally vest over a three-year period. The exercise price of stock options granted under the 2017 Plan must be at least equal to the fair market value of such shares on the date of grant. On July 15, 2021, the Board of Directors adopted an amendment to the 2017 Plan to increase the number of shares of the Company's common stock reserved for issuance thereunder by 1,000,000 shares. As of December 31, 2025, a total of 3,000,000 shares of the Company’s common stock have been reserved for issuance under the 2017 Plan. As of December 31, 2025, 394,467 shares of the Company’s common stock are issuable upon the exercise of outstanding stock options and vesting of RSUs granted under the 2017 Plan, and 1,306,714 shares of the Company’s common stock are available for future issuance under the 2017 Plan.

Stock-based compensation expense was as follows for the years ended December 31 (in thousands):

	*For the Year Ended*
	*December 31,*
	*2025*		*2024*		*2023*
Stock-based compensation:
Options:
Selling, general, and administrative	$	1,036	$	1,625	$	2,510
Research and development		170		290		611
Restricted stock units:
Selling, general, and administrative		3,247		3,941		4,398
Research and development		2,491		2,389		2,728
Total stock-based compensation expense	$	6,944	$	8,245	$	10,247

Stock Option Roll Forward

Activity with respect to options granted under the 2011 Plan and 2017 Plan is summarized as follows:

	*Shares*			*Weighted Average Exercise Price*		*Weighted Average Remaining Contractual Term (years)*		*Aggregate Intrinsic Value (in thousands)*
Outstanding at December 31, 2024		4,051,928		$	33.80
Granted		492,514			2.78
(Forfeited)		(84,954	)		3.57
(Exercised)		(55,882	)		2.33
(Expired)		(1,186,317	)		67.35
Outstanding at December 31, 2025		3,217,289		$	16.13		5.4	$	3,609
Vested and expected to vest at December 31, 2025		3,217,289		$	16.13		5.4	$	3,609
Exercisable		2,811,562		$	17.95		4.9	$	2,593

On December 31, 2025, total estimated unrecognized compensation cost related to non-vested stock options granted prior to that date was approximately $0.4 million, which is expected to be recognized over a weighted-average period of 1.1 years. At December 31, 2025, the total estimated unrecognized compensation cost related to non-vested RSUs was approximately $2.5 million, which is expected to be recognized over a weighted-average period of 1.3 years. The weighted-average grant date fair value of options granted during the years ended December 31, 2025, 2024 and 2023, was $1.95, $4.57 and $3.17 per share, respectively. The weighted-average grant date fair value of RSUs awarded during the year ended December 31, 2025, 2024 and 2023 was $3.36, $5.86 and $3.96, respectively.

Restricted Stock Unit Rollforward

	*Shares*			*Weighted Average Grant-Date Fair Value*
Nonvested shares at December 31, 2024		1,289,449		$	5.14
Granted		1,430,211		$	3.36
(Forfeited)		(138,380	)	$	4.03
(Vested)		(1,246,307	)	$	4.57
Nonvested shares at December 31, 2025		1,334,973		$	3.88

The entire disclosure for equity.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Note 9 - Debt - Schedule of Long Term Debt (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Total debt, inclusive of $2.0 million exit payment	$ 102,000
Less: unamortized debt issuance costs and discounts	(152)	$ (956)
Less: current portion	(22,523)	(45,329)
Less: debt repayment	(79,325)
Total long-term debt, net	$ 0	$ 21,719
Note Purchase Agreement [Member]
Maturity date	Jul. 23, 2026

Amount of unamortized debt discount (premium) and debt issuance costs.

+ References + Details

Note 4 - Prepaid Expenses and Other

12 Months Ended

Dec. 31, 2025

Prepaid Expense and Other Assets [Text Block]

Note 4—Prepaid Expenses and Other

Prepaid expenses and other consisted of the following at December 31 (in thousands):

	*December 31, 2025*		*December 31, 2024*
Current:
CRO services	$	37	$	81
Other clinical development		324		347
Insurance		1,128		1,078
Professional fees		381		731
Prepaid Taxes		117		21
Other		1,655		3,609
		3,642		5,867
Long-term:
CRO services		52		52
Insurance		8		11
Other clinical development		101		102
Other		2,673		119
		2,834		284
Totals	$	6,476	$	6,151

Other current prepaid amounts consist primarily of deposits, signing bonuses, licenses, subscriptions and software. Other long-term prepaid amounts consist primarily of funding for commercial copay support programs.

Note 12 - Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Unrecognized tax benefits	$ 3,045	$ 2,811	$ 2,522
Gross decreases - tax positions in prior period	(50)	(143)	(163)
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions	403	377	452
Unrecognized tax benefits	$ 3,398	$ 3,045	$ 2,811

Note 7 - Intangible Assets - Future Amortization Expense Maturity (Details) $ in Thousands	Dec. 31, 2025 USD ($)
Finite-Lived Intangible Asset, Expected Amortization, Year One	$ 9,739
Finite-Lived Intangible Asset, Expected Amortization, Year Two	9,739
Finite-Lived Intangible Asset, Expected Amortization, Year Three	9,739
Finite-Lived Intangible Asset, Expected Amortization, Year Four	9,739
Finite-Lived Intangible Asset, Expected Amortization, Year Five	2,436
Totals	$ 41,392

Note 5 - Property and Equipment

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment Disclosure [Text Block]

Note 5—Property and Equipment

Property and equipment consisted of the following at December 31 (in thousands):

	*December 31, 2025*			*December 31, 2024*
Leasehold improvements	$	2,549		$	3,779
Computer equipment		761			2,150
Telephone equipment		—			95
Furniture and fixtures		1,475			2,359
Total property and equipment		4,785			8,383
Less: accumulated depreciation		(4,598	)		(7,868	)
Property and equipment, net	$	187		$	515

For the years ended December 31, 2025, 2024 and 2023, the Company incurred depreciation expense of $0.4 million for each of the years ended December 31, 2025 and 2024.

Note 3 - Accounts Receivable, Net (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Accounts Receivable, Credit Loss Expense (Reversal)	$ (362)	$ (519)	$ 881

Note 8 - Accrued Expenses

12 Months Ended

Dec. 31, 2025

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 8—Accrued Expenses

Accrued expenses consisted of the following at December 31 (in thousands):

	*December 31, 2025*		*December 31, 2024*
Current:
Accrued royalties	$	15,858	$	10,169
Accrued CRO services		3,793		1,035
Accrued variable consideration		14,215		10,829
Accrued bonus		8,377		7,976
Accrued compensation		5,797		4,368
Accrued other clinical development		567		935
Accrued professional fees		132		341
Accrued legal fees		990		1,095
Accrued manufacturing costs		93		39
Other		209		111
	$	50,031	$	36,898
Long-term:
Accrued other liabilities		—		121
		—		121
Totals	$	50,031	$	37,019

Accrued variable consideration represents estimates of adjustments to product revenue, net for which reserves are established. Accrued royalties represent royalties incurred in connection with the Company’s license agreement with Pfizer. Accrued CRO services, accrued other clinical development expenses, and accrued legal fees represent the Company’s estimates of such costs and are recognized as incurred. Accrued compensation includes severance, commissions and vacation.

Note 13 - Commitments and Contingencies

12 Months Ended

Dec. 31, 2025

Commitments and Contingencies Disclosure [Text Block]

Note 13—Commitments and Contingencies

License Agreements

Pfizer License Agreement

In August 2011, the Company entered into an agreement pursuant to which Pfizer agreed to grant it a worldwide license for the development, manufacture and commercialization of PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357, and certain related compounds. The license is exclusive with respect to certain patent rights owned by or licensed to Pfizer. Under the agreement, the Company is obligated to commence a new clinical trial for a product containing one of these compounds within a specified period of time and to use commercially reasonable efforts to complete clinical trials and to achieve certain milestones as provided in a development plan. From the closing date of the agreement through December 31, 2011, Pfizer continued to conduct the existing clinical trials on behalf of the Company at the licensor’s sole expense. At the Company’s request, Pfizer agreed to continue to perform certain services in support of the existing clinical trials at the Company’s expense. These services will continue through the completion of the transitioned clinical trials. The license agreement “capped” the out of pocket expense the Company would be responsible to complete the then existing clinical trials. All agreed upon costs incurred by the Company above the “cost cap” would be reimbursed by Pfizer. The Company exceeded the “cost cap” during the fourth quarter of 2012. In accordance with the license agreement, the Company billed Pfizer for agreed upon costs above the “cost cap” until December 31, 2013.

On July 18, 2014, the Company entered into an amendment to the license agreement with Pfizer. The amendment amends the agreement to (i) reduce the royalty rate payable by the Company to Pfizer on sales of licensed products; (ii) release Pfizer from its obligation to pay for certain out-of-pocket costs incurred or accrued on or after January 1, 2014 to complete certain ongoing clinical studies; and (iii) provide that Pfizer and the Company will continue to cooperate to effect the transfer to the Company of certain records, regulatory filings, materials and inventory controlled by Pfizer as promptly as reasonably practicable.

As consideration for the license, the Company is required to make substantial payments upon the achievement of certain milestones totaling approximately $187.5 million if all such milestones are achieved, of which $102.5 million have been achieved as of December 31, 2025. In connection with the FDA approval of NERLYNX in July of 2017, the Company triggered a one-time milestone payment pursuant to the agreement. In June 2020, the Company entered into a letter agreement (the “Letter Agreement”), with Pfizer relating to the method of payment associated with a one-time milestone payment under the license agreement with Pfizer. The Letter Agreement permitted the Company to make the milestone payment in installments with the remaining amount payable to Pfizer (including interest). The milestone payment accrued interest at 6.25% per annum. The milestone payment including accrued interest of $1.8 million was paid in full in September 2021. In addition, the company reached a commercial milestone by achieving aggregate worldwide net sales of $250.0 million in calendar year 2022, resulting in a payable to Pfizer of $12.5 million as of December 31, 2022. The commercial milestone payable was paid in February 2023.

The Company may trigger additional milestone payments in the future. Should the Company commercialize any more of the compounds licensed from Pfizer or any products containing any of these compounds, the Company will be obligated to pay to Pfizer annual royalties at a fixed rate in the low to mid-teens of net sales of all such products, subject to certain reductions and offsets in some circumstances. The Company’s royalty obligation continues, on a product-by-product and country-by-country basis, until the later of (i) the last to expire licensed patent covering the applicable licensed product in such country, or (ii) the earlier of generic competition for such licensed product reaching a certain level in such country or expiration of a certain time period after first commercial sale of such licensed product in such country. In the event that the Company sublicenses the rights granted to the Company under the license agreement with Pfizer to a third party, the same milestone and royalty payments are required. The Company can terminate the license agreement at will, or for safety concerns, in each case upon specified advance notice.

Takeda License Agreement

In September 2022, the Company entered into an exclusive license agreement with Takeda to license the worldwide research and development and commercial rights to alisertib, a selective, small-molecule, orally administered inhibitor of Aurora Kinase A. Under the terms of the exclusive license agreement, the Company assumed sole responsibility for the global development and commercialization of alisertib. The Company paid Takeda an upfront license fee of $7.0 million in October 2022 and is eligible to receive potential future milestone payments of up to $287.3 million upon the Company’s achievement of certain regulatory and commercial milestones over the course of the exclusive license agreement, as well as tiered royalty payments for any net sales of alisertib. The Company recorded in-process research and development expense of $7.0 million in connection with the upfront payment related to the asset acquisition. As of December 31, 2025, no milestones had been accrued as the underlying contingencies were not considered probable.

Clinical Trial Contracts

The Company engages with CROs and contract manufacturing organizations (“CMOs”) in addition to engaging in contracts for the management of its ongoing clinical trials and pre-commercialization efforts. The Company may cancel these agreements with a 30 to 45 day written notice to the outside vendor. The Company would be obligated to pay for services rendered up to that point, which amounts to total contractual obligations of approximately $54.9 million within the next twelve months. The contracts also contain variable costs that are hard to predict as they are based on such things as patients enrolled and clinical trial sites, which can vary, and therefore, are not included in the total obligations amount. Included in the total contractual obligations amount above are payments to be made when milestones are reached. As of December 31, 2025, the Company's obligations for potential milestone payments totaled approximately $15.7 million. This amount will be paid by the Company if all milestones are reached and would reduce the overall contractual obligation if one or more milestone is never reached.

Legal Proceedings

The Company and certain of its executive officers were named as defendants in the lawsuits detailed below. The Company records a liability in the consolidated financial statements for loss contingencies when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required to estimate the amount and timing of a loss to be recorded.

Legal Malpractice Suit

On September 17, 2020, the Company filed a lawsuit against Hedrick Gardner Kincheloe & Garofalo, L.L.P. and David L. Levy, the attorneys who previously represented the Company in Eshelman v. Puma Biotechnology, Inc., et al. in the Superior Court of Mecklenburg County, North Carolina. The Company is alleging legal malpractice based on the defendants’ negligent handling of the defense of the Company in Eshelman v. Puma Biotechnology, Inc., et al. The Company is seeking recovery of the entire amount awarded in Eshelman v. Puma Biotechnology, Inc., et al. and all legal fees and expenses incurred in appealing from the judgment and retrying the damages phase of the trial. On November 23, 2020, the defendant filed an answer to the complaint denying the allegations of negligence. On August 19, 2022, the Company filed a voluntary dismissal of the legal malpractice action, without prejudice, to allow the Eshelman v. Puma Biotechnology, Inc., et al. to conclude before proceedings. On June 2, 2023, the Company re-filed the lawsuit against Hedrick Gardner Kincheloe & Garofalo, L.L.P. and David L. Levy, the attorneys who previously represented the Company in Eshelman v. Puma Biotechnology, Inc., et al. in the Superior Court of Mecklenburg County, North Carolina. On August 22, 2023, the defendants filed motions to dismiss the case. These motions were presented at a hearing on February 20, 2024. The Superior Court Judge granted the motions to dismiss on March 20, 2024. The Company appealed this ruling to the North Carolina Court of Appeals. On September 3, 2025, the Court of Appeals reversed the dismissal of the Company’s claim for legal malpractice and remanded the case to the Superior Court for further proceedings. The defendants filed a petition for discretionary review of this decision by the North Carolina Supreme Court on October 8, 2025. The Supreme Court has not decided whether to accept the case for review.

Patent-Related Proceedings

AstraZeneca Litigation

On September 22, 2021, the Company filed suit against AstraZeneca Pharmaceuticals, LP, AstraZeneca AB, and AstraZeneca PLC for infringement of United States Patent Nos. 10,603,314 (“the ‘314 patent”) and 10,596,162 (“the ‘162 patent”) (Puma Biotechnology, Inc. et al. v. AstraZeneca Pharmaceuticals LP et al., 1:21CV01338 (D. Del. Sep. 22, 2021)). The Company’s complaint alleges that AstraZeneca’s commercial manufacture, use, offer for sale, sale, distribution, and/or importation of Tagrisso® (osimertinib) products for the treatment of gefitinib and/or erlotinib-resistant non-small cell lung cancer infringes the ‘314 and ‘162 patents. The Company is an exclusive licensee of the ‘314 and ‘162 patents under the Pfizer Agreement. Wyeth is a co-plaintiff. Plaintiffs seek a judgment that AstraZeneca’s product infringes the asserted patents and an award of monetary damages in an amount to be proven at trial. AstraZeneca AB and AstraZeneca Pharmaceuticals LP filed an answer and counterclaims on November 5, 2021, including claims challenging the asserted patents as not infringed and/or invalid, and accusing plaintiffs of unclean hands and patent misuse. The parties stipulated to dismiss AstraZeneca PLC as a defendant and Pfizer as a Counterclaim Defendant on December 10, 2021, which the Court so ordered on December 13, 2021. The Company filed its answer to AstraZeneca’s counterclaims on December 17, 2021, denying those claims. The case was reassigned to visiting Judge Matthew Kennelly of the Northern District of Illinois. A Markman Hearing was conducted on March 17, 2023, and the Court issued its claim construction decision on March 29, 2023. Fact discovery closed on May 19, 2023, and expert discovery closed on November 17, 2023. The Court denied the parties’ respective motions for summary judgment and Daubert motions, other than to clarify that Plaintiffs’ damages cannot extend to any time period before the asserted patents were issued. The Court granted AstraZeneca’s motion to dismiss the Company as a Plaintiff on constitutional standing grounds but denied the motion to dismiss Wyeth as a Plaintiff on constitutional standing grounds. On April 29, 2024, the Court granted AstraZeneca’s motion to dismiss AstraZeneca’s counterclaims against the Company, which removed the Company from the case. Wyeth remained in the case as a Plaintiff and counterclaim-defendant. Under the Company’s worldwide exclusive license agreement with Pfizer, Inc. (the parent of Wyeth) as amended, the Company also maintains contractual rights to recover monetary damages in the AstraZeneca litigation, and those contractual rights are unaffected by the court’s March 18, 2024 and April 29, 2024 orders. A jury trial was held May 13-17, 2024. The jury found in favor of Wyeth and against AstraZeneca. In particular, the jury found that use of Tagrisso® according to each of the three FDA-approved indications infringes the asserted claims of the ‘314 and ‘162 patents, and that AstraZeneca induces that infringement. The jury further rejected AstraZeneca’s challenges to the validity of the patents, finding that they are not invalid. The jury awarded damages to Wyeth for past acts of infringement through December 31, 2023, in the amount of $107,500,000. A separate bench trial related to certain equitable claims and defenses raised by AstraZeneca was held before Judge Kennelly on June 20 and 25, 2024. On August 6, 2024, Judge Kennelly issued his ruling on the issues that were tried in the bench trial, finding for Wyeth and against AstraZeneca on all claims and defenses. The Court found that AstraZeneca had not proved its claim that Wyeth’s asserted patents were invalid as indefinite, or that Wyeth had committed acts that would give rise to findings of unclean hands, implied waiver, or patent misuse. AstraZeneca filed a motion challenging the jury’s verdict and requesting a new trial. Wyeth filed a motion requesting supplemental damages for past infringement from January 1, 2024, through the date of judgment; pre-and-post judgment interest, and ongoing royalties through the remaining term of the patents. Briefing on these motions from both sides was completed on July 16, 2024. On August 14, 2024, Judge Kennelly ruled on AstraZeneca’s motion challenging the jury’s verdict, granting it in part and denying it in part. The Court granted AstraZeneca’s motion for judgment as a matter of law that the '314 and '162 patents are invalid under 35 U.S.C. § 112 for lacking enablement and adequate written description as to a particular claim limitation. In all other respects, the Court denied AstraZeneca’s motion. The Court entered its final and appealable judgment accordingly. The Company respectfully disagrees with the Court’s ruling regarding invalidity with respect to the particular claim limitation. Wyeth filed a notice of appeal on September 12, 2024, appealing the District Court’s judgment as a matter of law, as well as other rulings and opinions of the Court adverse to Wyeth. On December 18, 2024, Wyeth filed its opening brief. On March 13, 2025, AstraZeneca filed its response brief. On March 20, 2025, non-parties Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC filed a motion for leave to file an amicus curiae brief in the Federal Circuit. The motion was granted on May 16, 2025. On June 6, 2025, Wyeth filed its reply brief. Briefing on the appeal is now complete, and the parties await further order from the Court.

Acebright China Litigation

On January 18, 2022, Shanghai Acebright Pharmaceuticals Group Co., Ltd. (“Acebright”) filed an abbreviated new drug application (“ANDA”) with the National Medical Products Administration in China (“NMPA”) seeking approval to market a generic version of the Company’s NERLYNX® (neratinib) tablet, 40mg in China. Acebright seeks approval prior to the expiration of three patents listed on the China Patent Information Registration Platform for Marketed Drugs (“Chinese Orange Book”), namely, Chinese Patent Nos. ZL201410082103.7, ZL201080060546.6, and ZL200880118789.3 (the “’789 patent” and collectively, the “NERLYNX® Patents”), alleging in a Type 4.2 patent declaration that its generic version of NERLYNX does not fall within the scope of the claims of NERLYNX® Patents listed in the Chinese Orange Book. The patent declaration of Acebright was published in the Chinese Orange Book on January 19, 2022. On March 2, 2022, the Company filed petitions with the China National Intellectual Property Administration (“CNIPA”) and requested administrative determination that Acebright’s generic neratinib tablet falls within the scope of the claims of NERLYNX® Patents listed in the Chinese Orange Book. The Company’s request for administrative determination was accepted by CNIPA on March 18, 2022. The Company has notified NMPA of the acceptance of the request for administrative determination for NMPA to institute a stay of Acebright’s ANDA for nine months. On July 11, 2022, CNIPA decided that claims 5 and 6 of Patent No. ZL200880118789.3 are not eligible for registration in the Chinese Orange Book on the ground that these two pharmaceutical method-of-use claims fall within the scope of “patents of crystalline forms,” which are not eligible for listing in the Chinese Orange Book. On September 9, 2022, CNIPA decided that the generic drug in Acebright’s ANDA does not fall within the protection scope of claims 1, 3, 5 and 6 of Patent No. ZL201410082103.7 and claims 1-4, 7 and 9-13 of Patent No. ZL201080060546.6. The three CNIPA administrative decisions on NERLYNX® Patents have lifted the stay of Acebright’s ANDA by NMPA. The Company has appealed each CNIPA administrative decision in January 2023 at the Beijing Intellectual Property Court (“BJIPC”). The three appeals were accepted by BJIPC on February 20, 2023. The Company also filed three civil complaints based on the three NERLYNX® Patents against Acebright with the BJIPC in July 2022 and requested court determination that Acebright’s generic neratinib tablet falls within the scope of the claims of NERLYNX® Patents. On May 6, 2023, the Company withdrew two civil lawsuits and two appeals in relation to Chinese Patent Nos. ZL201410082103.7 and ZL201080060546.6 at the BJIPC. On May 24, 2023, the BJIPC accepted the Company’s withdrawal request. On July 24, 2023, the Company withdrew the one remaining civil lawsuit and one appeal in relation to Chinese Patent No. ZL200880118789.3 at the BJIPC. On August 15, 2023, the BJIPC accepted the Company’s withdrawal request. On September 12, 2023, the NMPA approved Acebright’s ANDA to market a generic version of the Company’s NERLYNX® in China with the approval number of GuoYaoZhunZi H20234141.

On December 28, 2023, the Company filed a civil lawsuit against Acebright for infringement of the ’789 patent under Article 11 of the Chinese Patent Law before Jiangsu Nanjing Intermediate People’s Court. The Company’s complaint alleges that Acebright’s offer for sale of a generic version of the Company’s NERLYNX® product infringes the ’789 patent. The Company seeks a judgment that Acebright’s product infringes the ’789 patent and Acebright’s act of offer for sale shall be enjoined. On January 2, 2024, Jiangsu Nanjing Intermediate People’s Court accepted the civil complaint. An oral hearing was held on June 19, 2024, during which the Company amended its complaint to allege that Acebright making, selling and offering to sell the generic version of NERLYNX® infringes the ’789 patent. On July 24, 2024, the Company submitted a request to withdraw the lawsuit. On August 8, 2024, Jiangsu Nanjing Intermediate People’s Court accepted the withdrawal request.

On September 27, 2024, the Company filed an additional claim of infringement of the ‘789 patent against Acebright at Jiangsu Nanjing Intermediate People’s Court. On October 14, 2024, the Court accepted the complaint and designated case number (2024) Su 01 Min Chu 2192 to this case. On December 16, 2024, the Court conducted an evidence exchange hearing. On January 10, 2025, the Court conducted a hearing of party experts on the evaluation of evidence. On July 14, 2025, the Court conducted a hearing to examine evidence and debate merits of party arguments. On September 28, 2025, the Court issued a first-instance decision, deciding that Acebright’s product does not fall within the scope of the ‘789 patent, and Acebright did not infringe the ’789 patent; the Court also decided that the Company’s enforcement efforts were not malicious and did not amount to unfair competition.

Aosaikang China Litigation

On November 17, 2022, Jiangsu Aosaikang Pharmaceutical Co. Ltd. (“Aosaikang”) filed an ANDA with NMPA in China seeking approval to market a generic version of the Company’s NERLYNX®. The ANDA application No. is CYHS2202006. Aosaikang made Type 4.2 declarations against the four Orange Book Patents ZL201410082103.7, ZL201080060546.6, ZL200880118789.3 and ZL201710057547.9, alleging that its generic version of NERLYNX does not fall within the scope of the claims of the Orange Book patents. Aosaikang also alleged that Patents ZL200880118789.3 and ZL201710057547.9 are not eligible for Chinese Orange Book listing.

On December 28, 2022, the Company submitted four Article 76 petitions against the Aosaikang ANDA with the CNIPA and requested administrative determination that Aosaikang’s generic neratinib tablet falls within the scope of the claims of the four Orange Book patents. On January 6, 2023, the CNIPA accepted the Company’s request for administrative determination in relation to Patent Nos. ZL201410082103.7 and ZL201080060546.6. Also on January 6, 2023, the CNIPA declined to accept the Company’s request for administrative determination in relation to Patent Nos. ZL200880118789.3 and ZL201710057547.9, alleging that the listed claims are not eligible for registration in the Chinese Orange Book on the ground that these pharmaceutical method-of-use claims fall within the scope of “patents of crystalline forms,” which are not eligible for listing in the Chinese Orange Book. On January 28, 2023, the Company requested the NMPA to institute a nine-month stay against Aosaikang ANDA starting from the CNIPA’s acceptance of the Company’s request for administrative determination. On June 2, 2023, CNIPA decided that the generic drug in Aosaikang’s ANDA does not fall within the protection scope of claims 1, 3, 5 and 6 of Patent No. ZL201410082103.7 and claims 1-4, 7 and 9-13 of Patent No. ZL201080060546.6. The two CNIPA administrative decisions on NERLYNX® Patents have lifted the stay of Aosaikang’s ANDA by NMPA. On October 22, 2024, the NMPA approved Aosaikang’s ANDA to market a generic version of the Company’s NERLYNX® in China with the approval number of GuoYaoZhunZi H20249180.

Convalife China Litigation

Convalife Pharmaceuticals (Shanghai) Co., Ltd (“Convalife”) filed an ANDA with NMPA in China seeking approval to market a generic version of the Company’s NERLYNX®. The ANDA application No. is CYHS2202095. On December 23, 2022, Convalife made Type 4.2 declarations against the four Orange Book Patents ZL201410082103.7, ZL201080060546.6, ZL200880118789.3 and ZL201710057547.9, alleging that its generic version of NERLYNX does not fall within the scope of the claims of the Orange Book patents. Convalife also alleged that Patents ZL200880118789.3 and ZL201710057547.9 are not eligible for Chinese Orange Book listing.

On February 1, 2023, the Company submitted four Article 76 petitions against the Convalife ANDA with the CNIPA and requested administrative determination that Convalife’s generic neratinib tablet falls within the scope of the claims of the four Orange Book patents. On February 3, 2023, the CNIPA accepted the Company’s request for administrative determination in relation to Patent Nos. ZL201410082103.7 and ZL201080060546.6. Also on February 3, 2023, the CNIPA declined to accept the Company’s request for administrative determination in relation to Patent Nos. ZL200880118789.3 and ZL201710057547.9, alleging that the listed claims are not eligible for registration in the Chinese Orange Book on the ground that these pharmaceutical method-of-use claims fall within the scope of “patents of crystalline forms,” which are not eligible for listing in the Chinese Orange Book. On February 24, 2023, the Company requested the NMPA to institute a nine-month stay against Convalife ANDA starting from the CNIPA’s acceptance of the Company’s request for administrative determination. On June 2, 2023, CNIPA decided that the generic drug in Convalife’s ANDA does not fall within the protection scope of claims 1, 3, 5 and 6 of Patent No. ZL201410082103.7 and claims 1-4, 7 and 9-13 of Patent No. ZL201080060546.6. The two CNIPA administrative decisions on NERLYNX® Patents have lifted the stay of Convalife’s ANDA by NMPA. On June 28, 2024, the NMPA approved Convalife’s ANDA to market a generic version of the Company’s NERLYNX® in China with the approval number of GuoYaoZhunZi H20244222.

Kelun China Litigation

Hunan Kelun Pharmaceutical Co., Ltd. (“Kelun”) filed an ANDA with NMPA in China seeking approval to market a generic version of the Company’s NERLYNX®. The ANDA application No. is CYHS2300221. On January 28, 2023, Kelun made Type 4.2 declarations against the four Orange Book Patents ZL201410082103.7, ZL201080060546.6, ZL200880118789.3 and ZL201710057547.9, alleging that its generic version of NERLYNX does not fall within the scope of the claims of the Orange Book patents. Kelun also alleged that Patents ZL200880118789.3 and ZL201710057547.9 are not eligible for Chinese Orange Book listing.

On March 13, 2023, the Company submitted four Article 76 petitions against the Kelun ANDA with the CNIPA and requested administrative determination that Kelun’s generic neratinib tablet falls within the scope of the claims of the four Orange Book patents. On March 21, 2023, the CNIPA declined to accept the Company’s request for administrative determination in relation to Patent Nos. ZL200880118789.3 and ZL201710057547.9, alleging that the listed claims are not eligible for registration in the Chinese Orange Book on the ground that these pharmaceutical method-of-use claims fall within the scope of “patents of crystalline forms,” which are not eligible for listing in the Chinese Orange Book. On March 24, 2023, the CNIPA accepted the Company’s request for administrative determination in relation to Patent Nos. ZL201410082103.7 and ZL201080060546.6. On April 17, 2023, the Company requested the NMPA to institute a nine-month stay against Kelun’s ANDA starting from the CNIPA’s acceptance of the Company’s request for administrative determination. On September 14, 2023, the Company withdrew the two requests for administrative determination in relation to Chinese Patent Nos. ZL201410082103.7 and ZL201080060546.6 at the CNIPA. On September 25, 2023, the CNIPA accepted the Company’s withdrawal request. On September 9, 2025, the NMPA approved Kelun’s ANDA to market a generic version of the Company’s NERLYNX® in China with the approval number of GuoYaoZhunZi H20255337.

Demai Litigation

Zhengzhou Demai Pharmaceutical Co., Ltd (“Demai”) filed an ANDA with NMPA in China seeking approval to market a generic version of the Company’s NERLYNX®. The ANDA application No. is CYHS2402776. On August 26, 2024, Demai made a Type 4.2 declaration against Orange Book Patent ZL201410082103.7, alleging that its generic version of NERLYNX does not fall within the scope of the claims of this Orange Book patent. On September 30, 2024, the Company filed a lawsuit against Demai at the BJIPC based on Nerlynx Patent No. ZL201080060546.6 and on October 8, 2024, the Company filed a lawsuit against Demai at the BJIPC based on Nerlynx Patent No. ZL201410082103.7. On February 13, 2025, the Company withdrew the lawsuits from BJIPC, filed an Article 76 petition with the CNIPA against the Demai ANDA and requested administrative determination that Demai’s generic neratinib maleate tablet falls within the scope of the claims of Nerlynx Patent No. ZL201080060546.6. On February 21, 2025, the CNIPA accepted the Company’s petition and started examination. On March 18, 2025, the Company filed a request with the NMPA to set up a nine-month stay on Demai’s ANDA.

Hexal European Patent Opposition

An opposition was filed by Hexal AG (“Hexal”) on August 3, 2016 against European Patent No. EP2416774 which was licensed from Pfizer in 2011, and which claims neratinib for use in a method for treating HER-2/neu overexpressed/amplified cancer and improving IDFS, wherein the method comprises delivering neratinib therapy to HER-2/neu overexpressed/amplified cancer patients following the completion of at least one year of trastuzumab adjuvant therapy, and wherein the neratinib therapy comprises treating the cancer patients with neratinib for at least twelve months. An oral hearing was held on December 8, 2017, wherein the patent was maintained as granted. Following an appeal filed by Hexal, the Board of Appeal of the European Patent Office rejected the claims as granted and all pending auxiliary requests during the oral hearing of September 2, 2021. Before issuance of a decision, we withdrew approval of the text in which the patent was granted and all pending auxiliary requests, thereby revoking the patent and concluding the appeal. One European divisional application, namely EP15188350.1, was granted with the European patent number EP3000467 on March 1, 2023. Oppositions against EP3000467 were filed by Hexal on November 3, 2023, by Alfred E. Tiefenbacher (GmbH & Co. KG) on November 28, 2023 and by Generics (UK) Limited (“Generics”) on December 1, 2023. EP3000467 is used as the basic patent for Supplementary Protection Certificate applications for the EMA-approved NERLYNX® product, 17 of which have been granted, three proceedings have been stayed, and 11 are in active prosecution. The patentee response to the notice of opposition was filed on April 15, 2024, following which, all three opponents filed additional arguments in reply to the patentee’s submission. On February 6, 2025, the Company filed its response to the summons to attend oral proceedings, including six auxiliary requests. Alfred E. Tiefenbacher and Hexal filed their responses to the summons to oral proceedings on February 6 and 7, 2025, respectively. Hexal filed a further brief on March 19, 2025. Oral proceedings took place on April 9 and 10, 2025. EP3000467 was upheld as amended after the first instance hearing based on Auxiliary Request 1, which covers the EMA approved indication for NERLYNX® as an extended adjuvant therapy for treating early stage hormone receptor-positive HER-2-overexpressed/amplified breast cancer. The first instance decision may be appealed. Hexal filed an appeal on June 6, 2025, Generics filed an appeal on June 20, 2025 and Wyeth filed an appeal on June 30, 2025. On September 5, 2025, Wyeth filed its grounds of appeal, including nine auxiliary requests. On the same day, Hexal filed its grounds of appeal. Generics filed its grounds of appeal on September 4, 2025, and Alfred E. Tiefenbacher filed its grounds of appeal on September 1, 2025. On December 16, 2025, Alfred E. Tiefenbacher withdrew its appeal. Wyeth responded to the opponents’ grounds of appeal on January 12, 2026. One European divisional application is pending in the same family, namely EP 23157078.8. A response to the European Search Opinion (ESO) for this application was filed February 14, 2024. The first office action was issued on January 28, 2025 with a response to the first office action filed on July 22, 2025.

Note 2 - Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	For the Year Ended December 31,
	2025		2024		2023
Cost of sales	$	58,157	$	64,404	$	62,682
General and administrative		25,553		36,749		37,892
Commercialization		41,010		37,849		45,132
Research and development:
Clinical research and development		31,754		24,715		17,784
Medical affairs		5,494		4,605		6,751
Other research and development (1)		22,160		22,935		22,508
Operating costs and expenses		184,128		191,257		192,750
Stock based compensation		6,944		8,245		10,247
Total operating costs and expenses	$	191,072	$	199,502	$	202,997

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	For the Year Ended
	December 31,
	2025		2024
Options outstanding		3,504,811		3,533,693
Warrant outstanding		2,116,250		2,116,250
Unvested restricted stock units		110,902		734,236
Totals		5,731,963		6,384,179

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

December 31, 2025	*Level 1*		*Level 2*		*Level 3*		*Total*
Cash equivalents	$	5,060	$	18,710	$	—	$	23,770
U.S. Government securities		27,903		14,873		—		42,776
Corporate Bonds		—		6,865		—		6,865
Commercial paper		—		18,252		—		18,252
	$	32,963	$	58,700	$	—	$	91,663

December 31, 2024	*Level 1*		*Level 2*		*Level 3*		*Total*
Cash equivalents	$	16,996	$	38,102	$	—	$	55,098
U.S. Government securities		17,568		8,617		—		26,185
Commercial paper		—		5,561		—		5,561
Totals	$	34,564	$	52,280	$	—	$	86,844

Cash, Cash Equivalent, and Investment [Table Text Block]

	*Maturity*	*Amortized*		*Unrealized*					*Estimated*
December 31, 2025	*(in years)*	*Cost*		*Gains*		*Losses*			*Fair Value*
Cash equivalents		$	23,772	$	—	$	(2	)	$	23,770
U.S. Government securities	Less than 1		42,739		37		—			42,776
Corporate Bonds	Less than 1		6,866		1		(2	)		6,865
Commercial paper	Less than 1		18,250		3		(1	)	$	18,252
Totals		$	91,627	$	41	$	(5	)	$	91,663

	*Maturity*	*Amortized*		*Unrealized*					*Estimated*
December 31, 2024	*(in years)*	*Cost*		*Gains*		*Losses*			*Fair Value*
Cash equivalents		$	55,096	$	4	$	(2	)	$	55,098
U.S. Government securities	Less than 1		26,186	$	7	$	(8	)		26,185
Commercial paper	Less than 1		5,556		5		—			5,561
Totals		$	86,838	$	16	$	(10	)	$	86,844

Schedule of Inventory, Current [Table Text Block]

	*December 31, 2025*		*December 31, 2024*
Raw materials	$	3,212	$	7,183
Work-in-process (materials, labor and overhead)		1,343		758
Finished goods (materials, labor and overhead)		960		783
Total inventories	$	5,515	$	8,724

Note 6 - Leases - Future Minimum Lease Payments to be Received (Details) $ in Thousands	Dec. 31, 2025 USD ($)
2026	$ 81
Total	$ 81

Note 12 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ (18,700)
Income Tax Benefit Due to Research and Development Tax Credits	1,600
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions	403	$ 377	$ 452
Deferred Tax Assets, Gross	329,982	351,972	371,818
Deferred Tax Assets, Valuation Allowance	$ 324,787	$ 343,482	$ 368,751
Deferred Tax Assets, Valuation Allowance, Portion Released, Decrease in Tax Rate	9.07%
Open Tax Year	2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Domestic Tax Jurisdiction [Member]
Operating Loss Carryforwards	$ 827,800
Domestic Tax Jurisdiction [Member] \| Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	42,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	819,200
State and Local Jurisdiction [Member] \| Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	26,300
Forecasted Earnings in Upcoming Year [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	(3,800)
Stock Based Compensation [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ (14,900)

Note 10 - Stockholders' Equity - Restricted Stock Units (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Nonvested shares (in shares)	1,289,449
Nonvested, Beginning balance, Weighted Average Grant-Date Fair Value (in dollars per share)	$ 5.14
Granted shares (in shares)	1,430,211
Granted, Weighted Average Grant-Date Fair Value (in dollars per share)	$ 3.36	$ 5.86	$ 3.96
Forfeited shares (in shares)	(138,380)
Forfeited, Weighted Average Grant-Date Fair Value (in dollars per share)	$ 4.03
Vested shares (in shares)	(1,246,307)	(1,394,929)	(1,301,127)
Vested, Weighted Average Grant-Date Fair Value (in dollars per share)	$ 4.57
Nonvested shares (in shares)	1,334,973	1,289,449
Nonvested, Beginning balance, Weighted Average Grant-Date Fair Value (in dollars per share)	$ 3.88	$ 5.14

Note 12 - Income Taxes - Components of Net Deferred Tax Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Net operating loss carryforwards	$ 230,018	$ 232,184	$ 240,960
Business credit carryforwards	64,968	63,175	62,051
Compensation	13,104	26,081	37,946
Sec 174 R&D expenses	14,505	23,933	19,882
Accrued expenses	139	90	261
Carryforward of disallowed interest	0	0	1,477
Accrued legal verdict	0	0	1,976
Other deferred tax assets	5,718	4,745	4,231
Lease liabilities	1,530	1,764	3,034
Gross deferred tax assets	329,982	351,972	371,818
Valuation allowance	(324,787)	(343,482)	(368,751)
Net deferred tax assets	5,195	8,490	3,067
Other deferred tax liabilities	0	(70)	(149)
Right of use assets	(1,365)	(1,148)	(1,997)
Inventory	0	(197)	(921)
Total deferred tax liabilities	(1,365)	(1,415)	(3,067)
Net deferred tax assets (liability)	$ 3,830	$ 7,075	$ 0

Note 9 - Debt - Schedule of Debt Issuance Costs and Discounts (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Less: accumulated amortization	$ (5,258)	$ (4,454)
Included in current portion of debt	152	956
Athyrium Notes [Member]
Debt issuance costs and discounts	$ 5,410	$ 5,410

Amount of unamortized debt discount (premium) and debt issuance costs.

+ References + Details

Note 2 - Significant Accounting Policies - Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Anti-dilutive securities not included in calculation of diluted net loss per share (in shares)	5,731,963	6,384,179
Share-Based Payment Arrangement, Option [Member]
Anti-dilutive securities not included in calculation of diluted net loss per share (in shares)	3,504,811	3,533,693
Warrant [Member]
Anti-dilutive securities not included in calculation of diluted net loss per share (in shares)	2,116,250	2,116,250
Unvested Restricted Stock Units [Member]
Anti-dilutive securities not included in calculation of diluted net loss per share (in shares)	110,902	734,236

Note 11 - 401(k) Savings Plan (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Defined Contribution Plan, Cost	$ 1.6	$ 1.6	$ 1.6
First 3% of Each Participant's Contributions [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	100.00%
Second Two Percent Of Each Participants Contributions [Member]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	50.00%

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 29,635	$ 69,219
Marketable securities	67,893	31,746
Accounts receivable, net of allowance for credit loss of $0 and $362	53,654	32,011
Inventory	5,515	8,724
Prepaid expenses, current	3,642	5,867
Restricted cash, current	2,091	0
Other assets, current	256	91
Total current assets	162,686	147,658
Lease right-of-use assets, net	5,373	4,579
Property and equipment, net	187	515
Intangible assets, net	41,392	51,131
Restricted cash, long-term	0	2,091
Deferred tax assets	3,830	7,075
Prepaid expenses and other, long-term	2,834	284
Total assets	216,302	213,333
Current liabilities:
Accounts payable	5,056	5,509
Accrued expenses, current	50,031	36,898
Lease liabilities, current	1,314	5,540
Post-marketing commitment liability	2,187	2,835
Current portion of long-term debt	22,523	45,329
Other liabilities, current	142	0
Total current liabilities	81,253	96,111
Lease liabilities, long-term	4,709	1,494
Post-marketing commitment liability, long-term	0	1,763
Total long-term debt, net	0	21,719
Other liabilities, long-term	0	121
Total liabilities	85,962	121,208
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock - $.0001 par value per share; 100,000,000 shares authorized; 50,408,023 shares issued and outstanding at December 31, 2025 and 49,105,834 issued and outstanding at December 31, 2024	5	5
Additional paid-in capital	1,414,074	1,407,000
Accumulated other comprehensive income	36	6
Accumulated deficit	(1,283,775)	(1,314,886)
Total stockholders’ equity	130,340	92,125
Total liabilities and stockholders’ equity	$ 216,302	$ 213,333

Note 5 - Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2025

Property, Plant and Equipment [Table Text Block]

	*December 31, 2025*			*December 31, 2024*
Leasehold improvements	$	2,549		$	3,779
Computer equipment		761			2,150
Telephone equipment		—			95
Furniture and fixtures		1,475			2,359
Total property and equipment		4,785			8,383
Less: accumulated depreciation		(4,598	)		(7,868	)
Property and equipment, net	$	187		$	515

Insider Trading Policies and Procedures	12 Months Ended
Insider Trading Policies and Procedures	Dec. 31, 2025
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted [Flag]	true

Note 9 - Debt

12 Months Ended

Dec. 31, 2025

Debt Disclosure [Text Block]

Note 9—Debt

Long-term debt consisted of the following at December 31, 2025 (in thousands):

	*December 31, 2025*			*Maturity Date*
Total debt, inclusive of $2.0 million exit payment	$	102,000		July 23, 2026
Less: unamortized debt issuance costs and discounts		(152	)
Less: current portion		(22,523	)
Less: debt repayment		(79,325	)
Total long-term debt, net	$	(0	)

Athyrium Note Purchase Agreement

The Company issued senior notes for an aggregate principal amount of $100.0 million pursuant to a note purchase agreement dated July 23, 2021 by the Company, and its subsidiary, and Athyrium, as Administrative Agent, and certain other investor parties (the “Note Purchase Agreement”), with an initial maturity date of July 23, 2026 (the “Athyrium Notes”). The Athyrium Notes were issued for face amount of $100.0 million net of an original issue discount of $1.5 million. The Athyrium Notes also require a 2.0% exit payment to be made on each payment of principal. The borrowings under the Athyrium Notes, together with cash on hand, were used to repay the Company’s outstanding indebtedness, including the applicable exit and prepayment fees owed to lenders under its prior credit facility with Oxford. The Athyrium Notes are secured by substantially all of the Company’s assets. The Company incurred $1.9 million of deferred financing costs with the initial borrowing of the Athyrium Notes.

Interest on the Athyrium Notes is calculated in part based on the Secured Overnight Financing Rate (“SOFR”), which replaced the “London Interbank Offering Rate” as the floating benchmark for interest rate calculations applicable to the Athyrium Notes pursuant to the terms of the Third Amendment to Note Purchase Agreement dated as of September 16, 2022. (the “Third Amendment”). The modification of the Note Purchase Agreement pursuant to the Third Amendment did not meet the requirements of a debt extinguishment under ASC Topic 470-50 - Debt Modifications and Exchanges and no gain or loss was recognized. The Company performed a quantitative analysis and determined that the terms of the new debt and original debt instrument were not substantially different. Accordingly, the Third Amendment is accounted for as a debt modification.

Following the effectiveness of the Third Amendment, the Athyrium Notes bear interest at an annual rate equal to the sum of (a) eight percent (8.00%) plus (b) the lesser of (i) the sum of (x) three-month term SOFR for an interest period of three months plus (y) 0.26161% (26.161 basis points) and (ii) three and one-half of one percent (3.50%) per annum. Interest is payable quarterly on the last business day of March, June, September and December each year. In the second quarter of 2024, the Company began paying the principal payments required to be made quarterly at 11.11% of the original face amount. The remaining balance will be paid at maturity. Each principal payment also includes a 2.0% exit payment. Each quarterly principal payment approximates $11.1 million, and each quarterly exit fee payment approximates $0.2 million. As of December 31, 2025, the effective interest rate for the loan was 12.99%. The carrying amounts of the Company’s debt approximate fair value because of the short‑term nature and near‑term maturity of the instruments.

As of December 31, 2025, the Company may prepay the outstanding principal balance of the notes, in whole or in part, without premium or penalty.

The Athyrium Notes include affirmative and negative covenants applicable to the Company. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage, and satisfy certain requirements regarding deposit accounts. The negative covenants include, among others, restrictions on the Company’s transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions. The Company is also required to maintain minimum cash balances and achieve certain minimum product revenue targets, measured as of the last day of each fiscal quarter on a trailing year-to-date basis. As of December 31, 2025, the Company was in compliance with such covenants.

As of December 31, 2025, the principal balance outstanding under the Athyrium Notes was $22.5 million, representing all of the Company’s debt.

The future minimum principal and exit payments under the Athyrium Notes as of December 31, 2025, were as follows (in thousands):

	*Amount*
2026		22,675
Total	$	22,675

Debt Issuance Costs and Discounts

Debt issuance costs and discounts consist of the following (in thousands):

	*December 31, 2025*			*December 31, 2024*
Debt issuance costs and discounts (Athyrium Notes)	$	5,410		$	5,410
Less: accumulated amortization		(5,258	)		(4,454	)
Included in current portion of debt	$	152		$	956

Debt issuance costs and discounts are financing costs related to the Company’s outstanding debt. Amortization of debt issuance costs is expensed using the effective interest method and is included in interest expense in the consolidated statements of operations. For the years ended December 31, 2025, 2024 and 2023, the Company recorded approximately $0.8 million, $1.4 million and $1.3 million, respectively, of interest expense related to the amortization of debt issuance costs, discounts and exit fees in the consolidated statements of operations.

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Note 2 - Significant Accounting Policies - Segment Information (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2025

Dec. 31, 2024

Dec. 31, 2023

Cost of sales

$ 58,157

$ 64,404

$ 62,682

Total operating costs and expenses

62,068

54,935

50,382

Stock-based compensation

6,944

8,245

10,247

191,072

199,502

202,997

Operating Segments [Member]

Cost of sales

58,157

64,404

62,682

General and administrative

25,553

36,749

37,892

Commercialization

41,010

37,849

45,132

Operating costs and expenses

184,128

191,257

192,750

Stock-based compensation

6,944

8,245

10,247

Total operating costs and expenses

191,072

199,502

202,997

Operating Segments [Member] | Clinical Research [Member]

Operating Segments [Member] | Medical Affairs [Member]

31,754

24,715

17,784

Operating Segments [Member] | Other Research and Development [Member]

5,494

4,605

6,751

^[1]

$ 22,160

$ 22,935

$ 22,508

[1]	Other research and development expense include regulatory affairs, pharmacovigilance, quality assurance, chemical manufacturing and other costs.

Note 7 - Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Acquired and in-licensed rights	$ 102,500	$ 102,500
Less: accumulated amortization	(61,108)	(51,369)
Total intangible assets, net	$ 41,392	$ 51,131

Note 9 - Debt (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Debt [Table Text Block]

	*December 31, 2025*			*Maturity Date*
Total debt, inclusive of $2.0 million exit payment	$	102,000		July 23, 2026
Less: unamortized debt issuance costs and discounts		(152	)
Less: current portion		(22,523	)
Less: debt repayment		(79,325	)
Total long-term debt, net	$	(0	)

Schedule of Maturities of Long-Term Debt [Table Text Block]

	*Amount*
2026		22,675
Total	$	22,675

Schedule of Deferred Financing Costs [Table Text Block]

	*December 31, 2025*			*December 31, 2024*
Debt issuance costs and discounts (Athyrium Notes)	$	5,410		$	5,410
Less: accumulated amortization		(5,258	)		(4,454	)
Included in current portion of debt	$	152		$	956

Note 3 - Accounts Receivable, Net

12 Months Ended

Dec. 31, 2025

Accounts Receivable [Text Block]

Note 3—Accounts Receivable, Net

Accounts receivable, net consisted of the following (in thousands):

	*December 31, 2025*		*December 31, 2024*
Trade accounts receivable	$	38,146	$	26,362
Royalty revenue receivable		15,508		6,011
Total accounts receivable	$	53,654	$	32,373

Allowance for credit losses		—		(362	)
Total accounts receivable, net	$	53,654	$	32,011

Trade accounts receivable consist entirely of amounts owed from the Company’s customers related to product sales. Royalty revenue receivable represents amounts owed related to royalty revenue recognized based on the Company’s sub-licensees’ sales in their respective territories in the years ended December 31, 2025 and 2024.

For all accounts receivable, the Company recognizes credit losses based on lifetime expected losses to selling and general administrative expense in the consolidated statements of operations. In determining estimated credit losses, the Company evaluates its historical loss rates, current economic conditions and reasonable and supportable forecasts of future economic conditions. The Company recorded a recovery to the provision for credit loss recovery of $0.4 million in the year ended December 31, 2025. The Company recorded $0.5 million recovery to the provision for credit loss recovery in the year ended December 31, 2024 and a $0.9 million credit loss expense in the year ended December 31, 2023.

Note 10 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Millions				12 Months Ended
	Jun. 18, 2024	Jul. 15, 2021	Apr. 01, 2021	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Oct. 31, 2012	Oct. 31, 2011
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)				55,882	64,118	0
Common Stock, Shares Authorized (in shares)				100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)				$ 0.0001	$ 0.0001
Ordinary Shares Ownership Percentage								20.00%
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 1.95	$ 4.57	$ 3.17
Equity Incentive Plan Twenty Eleven [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)	3,000,000		2,000,000
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				17,529,412
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)				4,157,795
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				3,668,856
Employment Inducement Incentive Award Plan Twenty Seventeen [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized (in shares)		1,000,000
Common Stock, Capital Shares Reserved for Future Issuance (in shares)				3,000,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number (in shares)				394,467
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)				1,306,714
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)				3 years
Employment Inducement Incentive Award Plan Twenty Seventeen [Member] \| Maximum [Member]
Share-based Compensation Arrangement By Share-based Payment Award, Options Initial Contractual Term (Year)				10 years
Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							2,116,250
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)							$ 16
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period (in shares)				1,246,307	1,394,929	1,301,127
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 2.5
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				1 year 3 months 18 days
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				$ 3.36	$ 5.86	$ 3.96
Non-vested Stock Options [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 0.4
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				1 year 1 month 6 days

Note 4 - Prepaid Expenses and Other - Prepaid Expenses and Other (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
CRO services	$ 37	$ 81
Other clinical development	324	347
Insurance	1,128	1,078
Professional fees	381	731
Prepaid Taxes	117	21
Other	1,655	3,609
Total, long-term	3,642	5,867
CRO services	52	52
Insurance	8	11
Other clinical development	101	102
Other	2,673	119
Prepaid Expense and Other Assets, Noncurrent	2,834	284
Totals	$ 6,476	$ 6,151

Note 12 - Income Taxes - Cash Taxes Paid (Details)	12 Months Ended
Note 12 - Income Taxes - Cash Taxes Paid (Details)	Dec. 31, 2025 USD ($)
Federal income taxes paid (net of refunds)	$ 0
State income taxes paid (net of refunds)	1,092,000
Foreign income taxes paid (net of refunds)	179,000
Total income taxes paid (net of refunds)	1,271,000
Alabama Department of Revenue [Member]
State income taxes paid (net of refunds)	172,000
California Franchise Tax Board [Member]
State income taxes paid (net of refunds)	181,700
Indiana Department of Revenue [Member]
State income taxes paid (net of refunds)	199,000
Kentucky Department of Revenue [Member]
State income taxes paid (net of refunds)	181,400
New York State Division of Taxation and Finance [Member]
State income taxes paid (net of refunds)	77,800
Pennsylvania Department of Revenue [Member]
State income taxes paid (net of refunds)	121,600
South Korean National Tax Service [Member]
Foreign income taxes paid (net of refunds)	$ 179,120

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Total revenue	$ 228,371	$ 230,468	$ 235,637
Operating costs and expenses:
Cost of sales	58,157	64,404	62,682
Selling, general and administrative	70,847	80,163	89,933
Research and development	62,068	54,935	50,382
Total operating costs and expenses	191,072	199,502	202,997
Income from operations	37,299	30,966	32,640
Other income (expenses):
Interest income	4,078	4,724	2,605
Interest expense	(6,622)	(12,452)	(13,330)
Other income	1,027	862	759
Total other expenses, net	(1,517)	(6,866)	(9,966)
Income Before Income Taxes	35,782	24,100	22,674
Current income tax (expense)	(1,426)	(897)	(1,083)
Deferred income tax (expense) benefit	(3,245)	7,075	0
Net income	$ 31,111	$ 30,278	$ 21,591
Net income per share of common stock—basic (in dollars per share)	$ 0.62	$ 0.62	$ 0.46
Net income per share of common stock—diluted (in dollars per share)	$ 0.61	$ 0.62	$ 0.45
Weighted-average shares of common stock outstanding—basic (in shares)	50,011,485	48,648,701	47,134,331
Weighted-average shares of common stock outstanding—diluted (in shares)	50,653,283	49,100,433	47,550,852
Product [Member]
Total revenue	$ 204,074	$ 195,186	$ 203,107
Royalty [Member]
Total revenue	$ 24,297	$ 35,282	$ 32,530

Note 10 - Stockholders' Equity - Options Award Assumptions (Details) - Employee and Nonemployee Stock Option [Member]	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
Dividend yield	0.00%	0.00%
Expected volatility	81.50%	85.80%
Risk-free interest rate	4.40%	4.10%
Expected life in years (Year)	5 years 6 months 18 days	5 years 6 months 18 days

Note 3 - Accounts Receivable, Net - Schedule of Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Trade accounts receivable	$ 38,146	$ 26,362
Royalty revenue receivable	15,508	6,011
Total accounts receivable	53,654	32,373
Allowance for credit losses	0	(362)
Total accounts receivable, net	$ 53,654	$ 32,011

Note 2 - Significant Accounting Policies - Summary of Cash Equivalents and Short-term Investment (Details) - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Cash and cash equivalents	$ 29,635	$ 69,219
Unrealized gains	41	16
Unrealized losses	(5)	(10)
Totals, amortized cost	91,627	86,838
Totals, fair value	91,663	86,844
US Government Agencies Debt Securities [Member]
Investments, amortized cost	42,739	26,186
Unrealized gains	37	7
Unrealized losses	0	(8)
Investments, fair value	42,776	26,185
Corporate Bond Securities [Member]
Investments, amortized cost	6,866
Unrealized gains	1
Unrealized losses	(2)
Investments, fair value	6,865
Commercial Paper [Member]
Investments, amortized cost	18,250	5,556
Unrealized gains	3	5
Unrealized losses	(1)	0
Investments, fair value	18,252	5,561
Cash Equivalents [Member]
Cash and cash equivalents	23,772	55,096
Cash equivalents, unrealized gain	0	4
Cash equivalents, unrealized losses	(2)	(2)
Cash equivalents	$ 23,770	$ 55,098

Note 6 - Leases - Supplemental Cash Flow Information Related to Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2025 USD ($)
Operating cash flows used for operating leases (in thousands)	$ 6,469
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 4,123
Weighted-average remaining lease term (in years) (Year)	4 years 8 months 12 days
Weighted average discount rate	12.20%

Note 2 - Significant Accounting Policies (Details Textual) $ in Thousands	1 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($)	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)	Mar. 31, 2023 USD ($)
Number of Reportable Segments		1
Deferred Income Tax Expense (Benefit)		$ 3,245	$ (7,075)	$ (0)
Sublease Agreement, Potential Milestone Payments		579,800
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		(18,700)
Restricted Cash		2,100	2,100
Cash and Cash Equivalents, and Restricted Cash In Excess of Insured Limits		36,600
Accounts Receivable, Credit Loss Expense (Reversal)		(362)	(519)	881
Accounts Receivable, after Allowance for Credit Loss		53,654	32,011
Inventory, Net		5,515	8,724
Tangible Asset Impairment Charges		$ 0	0
Lessee, Operating Lease, Discount Rate		12.20%
Amortization of Intangible Assets		$ 9,700	9,700	$ 8,000
Finite-Lived Intangible Asset, Expected Amortization, Year One		9,739
Finite-Lived Intangible Asset, Expected Amortization, Year Five		2,436
Finite-Lived Intangible Asset, Expected Amortization, Year Two		9,739
Finite-Lived Intangible Asset, Expected Amortization, Year Three		9,739
Finite-Lived Intangible Asset, Expected Amortization, Year Four		9,739
Pfizer License Agreement [Member]
Revenue from Contract with Customer, Including Assessed Tax					$ 250,000
Potential Milestone Payments					12,500	$ 12,500
NERLYNX [Member]
Revenue from Contract with Customer, Including Assessed Tax					$ 250,000
Takeda License Agreement [Member]
Acquired In-process Research and Development	$ 7,000
Selling, General and Administrative Expenses [Member]
Operating Lease, Impairment Loss		$ 600
Computer Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)		3 years
Telephone Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)		3 years
Furniture and Fixtures [Member]
Property, Plant and Equipment, Useful Life (Year)		7 years
Europe [Member]
Inventory, Net		$ 4,500	1,200
Forecasted Earnings in Upcoming Year [Member]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		(3,800)
Customer Concentration Risk [Member] \| Customers With More than 10% Accounts Receivable [Member]
Accounts Receivable, after Allowance for Credit Loss		$ 38,900	$ 22,900
Customer Concentration Risk [Member] \| Revenue Benchmark [Member]
Number of Major Customers		5	4	4
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer 1 [Member]
Concentration Risk, Percentage		27.30%	28.40%	31.40%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer 2 [Member]
Concentration Risk, Percentage		17.00%	18.80%	17.20%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer 3 [Member]
Concentration Risk, Percentage		16.40%	14.10%	15.20%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer 4 [Member]
Concentration Risk, Percentage		13.10%	12.30%	11.90%
Customer Concentration Risk [Member] \| Revenue Benchmark [Member] \| Customer 5 [Member]
Concentration Risk, Percentage		10.60%
Reclassified to Non-cash Items [Member]
Deferred Income Tax Expense (Benefit)			$ (7,100)

Note 4 - Prepaid Expenses and Other (Tables)

12 Months Ended

Dec. 31, 2025

Prepaid Expense and Other Assets [TableText Block]

	*December 31, 2025*		*December 31, 2024*
Current:
CRO services	$	37	$	81
Other clinical development		324		347
Insurance		1,128		1,078
Professional fees		381		731
Prepaid Taxes		117		21
Other		1,655		3,609
		3,642		5,867
Long-term:
CRO services		52		52
Insurance		8		11
Other clinical development		101		102
Other		2,673		119
		2,834		284
Totals	$	6,476	$	6,151

Note 10 - Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Share-based compensation expense	$ 6,944	$ 8,245	$ 10,247
Share-Based Payment Arrangement, Option [Member] \| Selling, General and Administrative Expenses [Member]
Share-based compensation expense	1,036	1,625	2,510
Share-Based Payment Arrangement, Option [Member] \| Research and Development Expense [Member]
Share-based compensation expense	170	290	611
Restricted Stock Units (RSUs) [Member] \| Selling, General and Administrative Expenses [Member]
Share-based compensation expense	3,247	3,941	4,398
Restricted Stock Units (RSUs) [Member] \| Research and Development Expense [Member]
Share-based compensation expense	$ 2,491	$ 2,389	$ 2,728

Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2025

Accounting Policies [Abstract]

Consolidation, Policy [Policy Text Block]

Principles of Consolidation

The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

Segment Reporting, Policy [Policy Text Block]

Segment Reporting

	For the Year Ended December 31,
	2025		2024		2023
Cost of sales	$	58,157	$	64,404	$	62,682
General and administrative		25,553		36,749		37,892
Commercialization		41,010		37,849		45,132
Research and development:
Clinical research and development		31,754		24,715		17,784
Medical affairs		5,494		4,605		6,751
Other research and development (1)		22,160		22,935		22,508
Operating costs and expenses		184,128		191,257		192,750
Stock based compensation		6,944		8,245		10,247
Total operating costs and expenses	$	191,072	$	199,502	$	202,997

(1) Other research and development expense includes regulatory affairs, pharmacovigilance, quality assurance, chemical manufacturing and other costs.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Reclassification, Comparability Adjustment [Policy Text Block]

Reclassifications

Earnings Per Share, Policy [Policy Text Block]

Net Income per Share of Common Stock

	For the Year Ended
	December 31,
	2025		2024
Options outstanding		3,504,811		3,533,693
Warrant outstanding		2,116,250		2,116,250
Unvested restricted stock units		110,902		734,236
Totals		5,731,963		6,384,179

Revenue [Policy Text Block]

Revenue Recognition

Product Revenue, Net

Product revenue also consists of product sales under sub-license agreements to our sub-licensees, who then sell into their respective international territories.

Shipping and handling costs for product shipments occur prior to the customer obtaining control of the goods and are recorded in cost of sales.

Reserves for Variable Consideration

Trade Discounts and Allowances

Product Returns

Provider Chargebacks and Discounts

Government Rebates

Payor Rebates

Other Incentives

License Revenue

Royalty Revenue

Royalties, Policy [Policy Text Block]

Royalty Expenses

Legal Costs, Policy [Policy Text Block]

Legal Contingencies and Expense

Research and Development Expense, Policy [Policy Text Block]

Research and Development Expenses

Share-Based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

Stock Option Awards

Restricted Stock Units

Warrants

Income Tax, Policy [Policy Text Block]

Income Taxes

Fair Value of Financial Instruments, Policy [Policy Text Block]

Financial Instruments

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

The Company classifies all highly liquid instruments with an original maturity of three months or less as cash equivalents.

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]

Restricted Cash

Marketable Securities, Policy [Policy Text Block]

Investment Securities

Fair Value Measurement, Policy [Policy Text Block]

Assets Measured at Fair Value on a Recurring Basis

Level 1:

Quoted prices in active markets for identical assets or liabilities.

Level 2:

Level 3:

Valuations derived from valuation techniques in which one or more significant inputs are unobservable.

December 31, 2025	*Level 1*		*Level 2*		*Level 3*		*Total*
Cash equivalents	$	5,060	$	18,710	$	—	$	23,770
U.S. Government securities		27,903		14,873		—		42,776
Corporate Bonds		—		6,865		—		6,865
Commercial paper		—		18,252		—		18,252
	$	32,963	$	58,700	$	—	$	91,663

December 31, 2024	*Level 1*		*Level 2*		*Level 3*		*Total*
Cash equivalents	$	16,996	$	38,102	$	—	$	55,098
U.S. Government securities		17,568		8,617		—		26,185
Commercial paper		—		5,561		—		5,561
Totals	$	34,564	$	52,280	$	—	$	86,844

The following tables summarize the Company’s short-term investments (in thousands):

	*Maturity*	*Amortized*		*Unrealized*					*Estimated*
December 31, 2025	*(in years)*	*Cost*		*Gains*		*Losses*			*Fair Value*
Cash equivalents		$	23,772	$	—	$	(2	)	$	23,770
U.S. Government securities	Less than 1		42,739		37		—			42,776
Corporate Bonds	Less than 1		6,866		1		(2	)		6,865
Commercial paper	Less than 1		18,250		3		(1	)	$	18,252
Totals		$	91,627	$	41	$	(5	)	$	91,663

	*Maturity*	*Amortized*		*Unrealized*					*Estimated*
December 31, 2024	*(in years)*	*Cost*		*Gains*		*Losses*			*Fair Value*
Cash equivalents		$	55,096	$	4	$	(2	)	$	55,098
U.S. Government securities	Less than 1		26,186	$	7	$	(8	)		26,185
Commercial paper	Less than 1		5,556		5		—			5,561
Totals		$	86,838	$	16	$	(10	)	$	86,844

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentration of Risk

Inventory, Policy [Policy Text Block]

Inventory

The Company’s inventory balances are as follows:

	*December 31, 2025*		*December 31, 2024*
Raw materials	$	3,212	$	7,183
Work-in-process (materials, labor and overhead)		1,343		758
Finished goods (materials, labor and overhead)		960		783
Total inventories	$	5,515	$	8,724

Property, Plant and Equipment, Policy [Policy Text Block]

Property and Equipment, Net

Lessee, Leases [Policy Text Block]

Leases

The Company is required to remeasure the lease liability and make an adjustment in the following instances:

License Fees and Intangible Assets [Policy Text Block]

License Fees and Intangible Assets

New Accounting Pronouncements, Policy [Policy Text Block]

Accounting Pronouncements Adopted During the Current Year

ASU 2023-09, Improvements to Income Tax Disclosures

Recently Issued Accounting Standards

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022	46,345,660
Balance at Dec. 31, 2022	$ 5	$ 1,388,358	$ 0	$ (1,366,755)	$ 21,608
Stock-based compensation	$ 0	10,247	0	0	10,247
Shares issued or restricted stock units vested under employee stock plans (in shares)	1,301,127
Shares issued or restricted stock units vested under employee stock plans	$ 0	0	0	0	0
Unrealized gain (loss) on available-for-sale securities, net of tax of $0	0	0	(4)	0	(4)
Net income	$ 0	0	0	21,591	21,591
Balance (in shares) at Dec. 31, 2023	47,646,787
Balance at Dec. 31, 2023	$ 5	1,398,605	(4)	(1,345,164)	53,442
Stock-based compensation	$ 0	8,245	0	0	8,245
Shares issued or restricted stock units vested under employee stock plans (in shares)	1,459,047
Shares issued or restricted stock units vested under employee stock plans	$ 0	150	0	0	150
Unrealized gain (loss) on available-for-sale securities, net of tax of $0	0	0	10	0	10
Net income	$ 0	0	0	30,278	$ 30,278
Balance (in shares) at Dec. 31, 2024	49,105,834				49,105,834
Balance at Dec. 31, 2024	$ 5	1,407,000	6	(1,314,886)	$ 92,125
Stock-based compensation	$ 0	6,944	0	0	6,944
Shares issued or restricted stock units vested under employee stock plans (in shares)	1,302,189
Shares issued or restricted stock units vested under employee stock plans	$ 0	130	0	0	130
Unrealized gain (loss) on available-for-sale securities, net of tax of $0	0	0	30	0	30
Net income	$ 0	0	0	31,111	$ 31,111
Balance (in shares) at Dec. 31, 2025	50,408,023				50,408,023
Balance at Dec. 31, 2025	$ 5	$ 1,414,074	$ 36	$ (1,283,775)	$ 130,340

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2

Note 9 - Debt (Details Textual) - USD ($) $ in Thousands			6 Months Ended	12 Months Ended
Note 9 - Debt (Details Textual) - USD ($) $ in Thousands	Sep. 16, 2022	Jul. 23, 2021	Jun. 30, 2024	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Long-Term Debt				$ 22,675
Note Purchase Agreement [Member]
Debt Instrument, Unamortized Discount, Total		$ 1,500
Debt Instrument, Periodic Payment, Exit Payment, Percent		2.00%
Debt Issuance Costs, Gross		$ 1,900
Debt Instrument, Interest Rate, Stated Percentage	8.00%		11.11%
Debt Instrument, Exit Payment Percent			2.00%
Debt Instrument, Periodic Payment, Principal			$ 11,100
Debt Instrument, Periodic Payment, Exit Payment			$ 200
Debt Instrument, Interest Rate, Effective Percentage				12.99%
Long-Term Debt				$ 22,500
Amortization of Debt Issuance Costs				$ 800	$ 1,400	$ 1,300
Note Purchase Agreement [Member] \| Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.26161%
Note Purchase Agreement [Member] \| Adjusted Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	3.50%
Oxford Finance Limited Liability Company [Member] \| Secured Promissory Notes [Member]
Line of Credit Facility, Maximum Borrowing Capacity		100,000
Debt Instrument, Face Amount		$ 100,000

Note 8 - Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2025

Schedule of Accrued Liabilities [Table Text Block]

	*December 31, 2025*		*December 31, 2024*
Current:
Accrued royalties	$	15,858	$	10,169
Accrued CRO services		3,793		1,035
Accrued variable consideration		14,215		10,829
Accrued bonus		8,377		7,976
Accrued compensation		5,797		4,368
Accrued other clinical development		567		935
Accrued professional fees		132		341
Accrued legal fees		990		1,095
Accrued manufacturing costs		93		39
Other		209		111
	$	50,031	$	36,898
Long-term:
Accrued other liabilities		—		121
		—		121
Totals	$	50,031	$	37,019

Note 9 - Debt - Future Minimum Principal Payments (Details) $ in Thousands	Dec. 31, 2025 USD ($)
2026	$ 22,675
Total	$ 22,675

Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1D
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(16)(a)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-4

Trading Arrangements, by Individual [Table]

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2025	Feb. 23, 2026	Jun. 30, 2025
Document Information [Line Items]
Entity Central Index Key	0001401667
Entity Registrant Name	PUMA BIOTECHNOLOGY, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2025
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2025
Document Transition Report	false
Entity File Number	001-35703
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	77-0683487
Entity Address, Address Line One	10880 Wilshire Boulevard, Suite 1700
Entity Address, City or Town	Los Angeles
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	90024
City Area Code	424
Local Phone Number	248-6500
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Trading Symbol	PBYI
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 145,200,000
Entity Common Stock, Shares Outstanding		50,876,487
Auditor Name	KPMG LLP
Auditor Location	Los Angeles, CA
Auditor Firm ID	185

Insider Trading Arrangements

3 Months Ended

12 Months Ended

Dec. 31, 2025

Material Terms of Trading Arrangement [Text Block]

ITEM 9B.

OTHER INFORMATION

During the three months ended December 31, 2025, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Non-Rule 10b5-1 Arrangement Terminated [Flag]

false

Rule 10b5-1 Arrangement Adopted [Flag]

false

Rule 10b5-1 Arrangement Terminated [Flag]

false

Non-Rule 10b5-1 Arrangement Adopted [Flag]

false

Note 12 - Income Taxes

12 Months Ended

Dec. 31, 2025

Income Tax Disclosure [Text Block]

Note 12—Income Taxes

The Company uses the asset and liability method of accounting for income taxes in accordance with Accounting Standards Codification Topic 740, “Income Taxes.” Under this method, income tax expense is recognized for the amount of: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date.

The components of income before income taxes for the years ended December 31 (in thousands) are as follows:

	*2025*		*2024*		*2023*
Domestic	$	35,782	$	24,100	$	22,674
Foreign		—		—		—
Income Before Income Taxes	$	35,782	$	24,100	$	22,674

The provisions of income taxes are summarized as follows (in thousands):

	*2025*		*2024*			*2023*
Current:
Federal	$	—	$	—		$	—
State		1,247		722			905
Foreign		179		175			178
		1,426		897			1,083
Deferred:
Federal		3,052		(6,632	)		—
State		193		(443	)		—
		3,245		(7,075	)		—
Total	$	4,671	$	(6,178	)	$	1,083

Reconciliation of Statutory Federal Income Tax Rate to the Effective Income Tax Rate

The Company has elected to prospectively adopt the guidance in ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Taxes Disclosures, or ASU 2023-09. The following table is a reconciliation of the U.S. federal statutory rate of 21% to the Company's effective rate for the year ended December 31, 2025 in accordance with the guidance in ASU No. 2023-09:

	*2025*
	*Amount*			*Percentage*
U.S. federal statutory income tax		7,514			21.0	%
State and local income taxes, net of federal income tax effect (1)		1,238			3.5	%
Foreign tax effects		179			0.5	%
Tax credits		(1,280	)		-3.6	%
Change in valuation allowance		(18,639	)		-52.1	%
Non-taxable or non-deductible items
SBC Options		14,619			40.9	%
Section 162(m)		777			2.2	%
Other nontaxable or nondeductible items		243			0.7	%
Other		20			0.1	%
Income tax expense		4,671			13.1	%

(1) State taxes in Kentucky and Indiana comprise the majority (greater than 50%) of the tax effect in this category.

As previously disclosed for the years ended December 31, 2024 and 2023, prior to the adoption of ASU 2023-09, the effective income tax rate differs from the statutory federal income tax rate as follows:

	2024			2023
Tax computed at the federal statutory rate	$	5,061		$	4,488
State taxes		744			1,312
Foreign taxes		175			178
Permanent items		12,946			4,837
R&D credits		(1,532	)		(1,806	)
Prior year adjustment		1,697			(1,715	)
Change in valuation allowance		(25,269	)		(6,211	)
Total provision	$	(6,178	)	$	1,083

Approximately $3.8 million of the $18.7 million change in valuation allowance is attributable to a partial valuation allowance release (see further discussion within the tax footnotes below). Approximately $15.0 million of tax expense is due to stock-based compensation expense shortfall, the expiration of vested stock options, and non-deductible stock-based compensation. Approximately $1.6 million of the tax benefits are due to R&D tax credits, net of a $0.4 million reserve related to unrecognized tax benefits for the method of allocation of expenses used in the R&D credit calculation.

Temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes give rise to the Company’s deferred income taxes. The components of the Company’s net deferred tax assets as of December 31, 2025, 2024 and 2023 are as follows (in thousands):

	*2025*			*2024*			*2023*
Deferred tax assets:
Net operating loss carryforwards	$	230,018		$	232,184		$	240,960
Business credit carryforwards		64,968			63,175			62,051
Compensation		13,104			26,081			37,946
Sec 174 R&D expenses		14,505			23,933			19,882
Accrued expenses		139			90			261
Carryforward of disallowed interest		—			—			1,477
Accrued legal verdict		—			—			1,976
Other deferred tax assets		5,718			4,745			4,231
Lease liabilities		1,530			1,764			3,034
Gross deferred tax assets		329,982			351,972			371,818
Valuation allowance		(324,787	)		(343,482	)		(368,751	)
Net deferred tax assets		5,195			8,490			3,067
Deferred tax liabilities:
Other deferred tax liabilities		—			(70	)		(149	)
Right of use assets		(1,365	)		(1,148	)		(1,997	)
Inventory		—			(197	)		(921	)
Total deferred tax liabilities		(1,365	)		(1,415	)		(3,067	)
Net deferred tax assets (liability)	$	3,830		$	7,075		$	—

As of December 31, 2024, the Company had deferred tax assets totaling $352.0 million, primarily attributable to net operating loss (NOL) carryforwards and R&D tax credit carryforwards. A valuation allowance of $343.5 million had been established in prior periods as the management concluded it was more likely than not that the asset will not be realized.

During the year ended December 31, 2025, the Company has recorded a net decrease in the valuation allowance of $18.7 million. The decrease is attributable to recognizing $14.9 million of net deferred tax assets primarily related to utilization of net operating losses and stock-based compensation. The remaining change is attributable to a partial valuation allowance release of $3.8 million driven by forecasted earnings in 2026. The remaining valuation allowance of $324.8 million reserves against deferred tax assets that are more likely than not to not be recognized, as the Company's forecasted profitability is uncertain beyond 2026.

Management’s decision to release a portion of the valuation allowance was based on an assessment of both positive and negative evidence, as required under ASC 740.

Positive evidence supporting the partial release included:

•

Three consecutive years of cumulative pretax income, indicating a trend of profitability.

•

Projected earnings in 2026, increasing the likelihood of realizing certain deferred tax assets.

Negative evidence that led to retaining a portion of the valuation allowance included:

•

Competitive pressure in the oncology market, including the risks of alternative treatments gaining market share or impacting pricing flexibility.

•

Ability to generate sustained profitability remains uncertain due to dependence on NYRLYNX as a primary commercial product

•

Future profits are contingent on the successful clinical development and approval of pipeline products

•

Future limitations on the utilization of NOL and R&D tax credits.

•

The Company does not have material deferred tax liabilities (DTLs) to offset deferred tax assets (DTAs).

As of December 31, 2025, the remaining valuation allowance of $324.8 million continues to reflect management’s assessment of uncertainties related to the realization of certain net operating losses and R&D tax credit carryforwards, which remain subject to expiration or utilization limitations. The decision to retain the remaining valuation allowance was based on inherent uncertainty in forecasting taxable income beyond 2026.

The partial release of the valuation allowance decreased the effective tax rate by 9.07%.

Management will continue to evaluate the realizability of deferred tax assets on a quarterly basis.

At December 31, 2025, the Company had federal and state net operating loss carryforwards respectively of approximately $827.8 million and $819.2 million, respectively, which will begin to expire respectively in 2035 and 2036. At December 31, 2025, the Company also has federal research and development credit carryforwards of approximately $42.0 million. If not utilized, the research and development credit carryforwards will begin expiring in 2033. The Company has state research and development credit carryforwards of approximately $26.3 million which do not expire. Pursuant to the Internal Revenue Code, Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards could be limited if a cumulative change in ownership of more than 50% occurs within a three-year period. The Company performed an assessment of the potential limitation on net operating loss and credit carryforwards, and concluded that there will be no limitation for the tax year 2025 for federal purposes.

The following is a tabular reconciliation of the total amounts of unrecognized tax benefits at December 31 (in thousands):

	*2025*			*2024*			*2023*
Unrecognized tax benefits - January 1	$	3,045		$	2,811		$	2,522
Gross decreases - tax positions in prior period		(50	)		(143	)		(163	)
Gross increases - tax positions in a current period		403			377			452
Unrecognized tax benefits - December 31	$	3,398		$	3,045		$	2,811

During prior period we completed research and development credit study. As a result of the study, we computed our credit under safe harbor rules which when applied consistently result in more conservative approach of calculating the amount of credit. We concluded that a release of uncertain tax benefits for the portion of the R&D credit attributable to safe harbor was appropriate and released a portion of previously recorded uncertain tax positions reserve.

The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by the federal and state jurisdictions where applicable. The Company is currently pending a federal income tax examination for the fiscal year ended December 31, 2022. The Company’s tax years for 2012 and forward are subject to examination by the federal and California tax authorities due to the carryforward of unutilized net operating losses and research and development credits.

Income Tax Payments

Disclosed below is a summary of income taxes paid by jurisdiction pursuant to the disclosure requirements of ASU 2023-09 for the year ended December 31, 2025:

	*2025*
Federal income taxes paid (net of refunds)		—
State income taxes paid (net of refunds)		1,092
Foreign income taxes paid (net of refunds)		179

Total income taxes paid (net of refunds)		1,271

Income taxes paid (net of refunds) exceeded five percent of total income taxes paid (net of refunds) in the following jurisdictions:

State	*2025*
Alabama		172,000
California		181,700
Indiana		199,000
Kentucky		181,400
New York		77,800
Pennsylvania		121,600

Foreign	*2025*
South Korea		179,120

The entire disclosure for income tax.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477617/942-740-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 740
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478822/944-740-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2